[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 209
1. Iravanloo G, Nozarian Z, Sarrafpour B, Motahhary P: Sclerosing stromal tumor of the ovary. Arch Iran Med; 2008 Sep;11(5):561-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing stromal tumor of the ovary.
  • Sclerosing stromal tumors are benign ovarian neoplasms of the sex cord stromal category which occur predominantly in the second and third decades of life.
  • Herein, we report a 26-year-old woman who developed a sclerosing stromal tumor of the ovary with irregular menses but normal hormonal status.
  • She was suspected to have a malignant tumor and underwent bilateral oophorectomy.
  • Other ovarian stromal tumors include fibroma and thecoma which tend to occur in the fifth and sixth decades of life.
  • It is, therefore, necessary to keep in mind the possibility of a sclerosing stromal tumor in a young woman.
  • [MeSH-major] Ovarian Neoplasms. Sex Cord-Gonadal Stromal Tumors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759528.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


2. Jeoung HY, Choi HS, Lim YS, Lee MY, Kim SA, Han SJ, Ahn TG, Choi SJ: The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors. J Gynecol Oncol; 2008 Dec;19(4):229-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of sonographic morphology indexing and serum CA-125 for preoperative differentiation of malignant from benign ovarian tumors in patients after operation with ovarian tumors.
  • OBJECTIVE: To evaluate the value of sonographic morphology indexing (MI) system and serum CA-125 levels in the assessment of the malignancy risk in patients with ovarian tumors.
  • METHODS: From September 2000 to July 2006, 202 patients who underwent surgery for ovarian tumors were reviewed retrospectively.
  • The association of the final pathologic diagnosis with the MI score and serum CA-125 level were examined.
  • RESULTS: There were 26 malignant tumors out of 141 ovarian tumors with a MI >/=5 (18%).
  • There were 22 malignant tumors out of 54 ovarian tumors with serum CA-125 >30 u/ml (41%).
  • CONCLUSION: The sonographic MI system is an accurate and simple method to differentiate a malignant tumor from a benign ovarian tumor.
  • The accuracy of the sonographic MI system improved when the serum CA-125 level was considered and ovarian teratomas were excluded.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1985 May;155(2):477-8 [3885313.001]
  • [Cites] Int J Gynecol Pathol. 1982;1(1):3-16 [7184889.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):46-50 [14529661.001]
  • [Cites] Radiol Clin North Am. 2003 Jul;41(4):799-811 [12899493.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2001 May;96(1):80-4 [11311766.001]
  • [Cites] Radiographics. 2001 Mar-Apr;21(2):475-90 [11259710.001]
  • [Cites] CA Cancer J Clin. 1999 Sep-Oct;49(5):297-320 [11198956.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):454-9 [10831359.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):410-2 [10831351.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Radiology. 1999 Jul;212(1):19-27 [10405715.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):3-7 [9570990.001]
  • [Cites] Obstet Gynecol. 1995 Jan;85(1):48-52 [7800323.001]
  • [Cites] Gynecol Oncol. 1994 Nov;55(2):174-8 [7959280.001]
  • [Cites] Gynecol Oncol. 1993 Oct;51(1):7-11 [8244178.001]
  • [Cites] Obstet Gynecol. 1991 Jul;78(1):70-6 [2047071.001]
  • [Cites] Gynecol Oncol. 1990 Oct;39(1):69-71 [2227575.001]
  • [Cites] Br J Obstet Gynaecol. 1990 Oct;97(10):922-9 [2223684.001]
  • (PMID = 19471578.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676475
  • [Keywords] NOTNLM ; CA-125 antigen / ROC curve / Teratoma / Ultrasonogram (morphology indexing)
  •  go-up   go-down


3. Nowak M, Klink M, Glowacka E, Sulowska Z, Kulig A, Szpakowski M, Szyllo K, Tchorzewski H: Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells. Scand J Immunol; 2010 Feb;71(2):91-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Production of cytokines during interaction of peripheral blood mononuclear cells with autologous ovarian cancer cells or benign ovarian tumour cells.
  • Cytokines produced by tumour and immune cells may play a significant role in a modulation of immune cells response against tumour.
  • We investigated an ability of peripheral blood mononuclear cells (PBMC) of patients with early and advanced stages of ovarian cancer and from non-cancer patients to produce various cytokines in the presence or absence of autologous ovarian cancer (OC) cells or benign ovarian tumour (BOT) cells.
  • PBMC of patients with ovarian cancer or benign ovarian tumour generated comparable amounts of interleukin 6 and 10 (IL-6, IL-10), and transforming growth factor beta1 (TGF-beta1).
  • PBMC of the patients with cancer produced higher amount of tumour necrosis factor alpha (TNF-alpha) than PBMC of non-cancer patients.
  • [MeSH-major] Cell Communication / immunology. Cytokines / biosynthesis. Leukocytes, Mononuclear / immunology. Ovarian Neoplasms / immunology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20384860.001).
  • [ISSN] 1365-3083
  • [Journal-full-title] Scandinavian journal of immunology
  • [ISO-abbreviation] Scand. J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


Advertisement
4. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szymañska A, Szymañska-Pasternak J, Dyrskjot L, Butzow R, Orntoft TF, Launonen V, Lubiñski J, Aaltonen LA: Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet; 2006 Jul;14(7):880-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma.
  • HLRCC is characterized by benign leiomyomas of the skin and the uterus, renal cell carcinoma, and uterine leiomyosarcoma.
  • The aim of this study was to identify new families with FH mutations, and to further examine the tumor spectrum associated with FH mutations.
  • FH germline mutations were screened from 89 patients with RCC, skin leiomyomas or ovarian tumors.
  • Subsequently, 13 ovarian and 48 bladder carcinomas were analyzed for somatic FH mutations.
  • Two patients diagnosed with ovarian mucinous cystadenoma (two out of 33, 6%) were found to be FH germline mutation carriers.
  • These results suggest that benign ovarian tumors may be associated with HLRCC.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Fumarate Hydratase / genetics. Germ-Line Mutation. Neoplastic Syndromes, Hereditary / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Renal Cell / genetics. Cystadenocarcinoma, Mucinous / genetics. Female. Genes, Dominant. Humans. Kidney Neoplasms / genetics. Leiomyoma / genetics. Male. Neoplasms / genetics. Skin Neoplasms / genetics. Urinary Bladder Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16639410.001).
  • [ISSN] 1018-4813
  • [Journal-full-title] European journal of human genetics : EJHG
  • [ISO-abbreviation] Eur. J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 4.2.1.2 / Fumarate Hydratase
  •  go-up   go-down


5. Tamada T, Sone T, Tanimoto D, Higashi H, Miyoshi H, Egashira N, Yamamoto A, Imai S: MRI appearance of primary giant ovarian leiomyoma in a hysterectomised woman. Br J Radiol; 2006 Oct;79(946):e126-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI appearance of primary giant ovarian leiomyoma in a hysterectomised woman.
  • Primary leiomyoma is a rare, benign tumour of the ovary.
  • We describe the MRI features of an ovarian leiomyoma identified in a 51-year-old woman after hysterectomy.
  • The tumour appeared as a well-circumscribed low signal intensity mass on T(1) weighted imaging, with mixed signal intensity on T2 weighted imaging.
  • This case suggests the potential usefulness of dynamic contrast-enhanced MRI for the diagnosis of ovarian leiomyoma.
  • [MeSH-major] Leiomyoma / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Hysterectomy. Magnetic Resonance Imaging. Middle Aged. Uterine Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980667.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 16
  •  go-up   go-down


6. Kumar SR, Masood R, Spannuth WA, Singh J, Scehnet J, Kleiber G, Jennings N, Deavers M, Krasnoperov V, Dubeau L, Weaver FA, Sood AK, Gill PS: The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer; 2007 Apr 10;96(7):1083-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
  • We wanted to determine the biological role of EphB4 in ovarian cancer.
  • We studied the expression of EphB4 in seven normal ovarian specimens and 85 invasive ovarian carcinomas by immunohistochemistry.
  • EphB4 expression was largely absent in normal ovarian surface epithelium, but was expressed in 86% of ovarian cancers.
  • We also studied the biological significance of EphB4 expression in ovarian tumour cells lines in vitro and in vivo.
  • All five malignant ovarian tumour cell lines tested expressed higher levels of EphB4 compared with the two benign cell lines.
  • Treatment of malignant, but not benign, ovarian tumour cell lines with progesterone, but not oestrogen, led to a 90% reduction in EphB4 levels that was associated with 50% reduction in cell survival.
  • Inhibition of EphB4 expression by specific siRNA or antisense oligonucleotides significantly inhibited tumour cell viability by inducing apoptosis via activation of caspase-8, and also inhibited tumour cell invasion and migration.
  • Furthermore, EphB4 antisense significantly inhibited growth of ovarian tumour xenografts and tumour microvasculature in vivo.
  • Inhibition of EphB4 may hence have prognostic and therapeutic utility in ovarian carcinoma.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2001 Feb 15;230(2):139-50 [11161568.001]
  • [Cites] Br J Cancer. 2007 Jan 15;96(1):151-6 [17179984.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):220-6 [12562648.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):603-10 [12594815.001]
  • [Cites] Pathol Oncol Res. 2004;10(1):26-33 [15029258.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5583-8 [15067119.001]
  • [Cites] Cell. 1998 May 29;93(5):741-53 [9630219.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):103-11 [9737787.001]
  • [Cites] Mol Cell. 1999 Sep;4(3):403-14 [10518221.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4623-32 [15930280.001]
  • [Cites] BMC Cancer. 2005;5:119 [16171530.001]
  • [Cites] Oncogene. 2006 Feb 2;25(5):769-80 [16205642.001]
  • [Cites] Panminerva Med. 2006 Mar;48(1):13-7 [16633327.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):15-21 [16499955.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):279-93 [16816380.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1236-48 [16615113.001]
  • [Cites] J Cell Sci. 2002 Jan 1;115(Pt 1):25-37 [11801721.001]
  • (PMID = 17353927.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / R01 CA079218; United States / NCI NIH HHS / CA / R01CA79218
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Progestins; 0 / RNA, Small Interfering; 4G7DS2Q64Y / Progesterone; EC 2.7.10.1 / Receptor, EphB4; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2360128
  •  go-up   go-down


7. Van Calster B, Valentin L, Van Holsbeke C, Testa AC, Bourne T, Van Huffel S, Timmerman D: Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models. BMC Med Res Methodol; 2010;10:96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel-based risk prediction models.
  • BACKGROUND: Hitherto, risk prediction models for preoperative ultrasound-based diagnosis of ovarian tumors were dichotomous (benign versus malignant).
  • We develop and validate polytomous models (models that predict more than two events) to diagnose ovarian tumors as benign, borderline, primary invasive or metastatic invasive.
  • However, discrimination between primary and metastatic invasive tumors decreased to near random levels.
  • CONCLUSIONS: We have developed models that successfully discriminate between benign, borderline, and invasive ovarian tumors.
  • The random discrimination between primary and metastatic invasive tumors on temporal/external validation demonstrated once more the necessity of validation studies.
  • [MeSH-major] Algorithms. Models, Statistical. Ovarian Neoplasms / ultrasonography. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):162-7 [11161854.001]
  • [Cites] Ultrasound Obstet Gynecol. 2010 Aug;36(2):226-34 [20455203.001]
  • [Cites] Neural Comput. 2002 May;14(5):1115-47 [11972910.001]
  • [Cites] Oncology. 2003;65(1):29-36 [12837980.001]
  • [Cites] Stat Med. 2000 Apr 30;19(8):1059-79 [10790680.001]
  • [Cites] Med Decis Making. 2001 Jan-Feb;21(1):45-56 [11206946.001]
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] Med Decis Making. 1999 Jan-Mar;19(1):78-89 [9917023.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8794-801 [16314639.001]
  • [Cites] Gynecol Oncol. 2006 Jan;100(1):185-91 [16216320.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 May;29(5):496-504 [17444557.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Aug;133(2):218-22 [16797823.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4440-7 [17671128.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4194-200 [17698805.001]
  • [Cites] J Clin Epidemiol. 2008 Feb;61(2):125-34 [18177785.001]
  • [Cites] J Clin Epidemiol. 2008 Feb;61(2):135-41 [18177786.001]
  • [Cites] Neural Netw. 2008 Mar-Apr;21(2-3):437-49 [18343309.001]
  • [Cites] Obstet Gynecol. 2009 Feb;113(2 Pt 1):384-94 [19155910.001]
  • [Cites] BMJ. 2009;338:b605 [19477892.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Lancet. 2009 Oct 17;374(9698):1371-82 [19793610.001]
  • [Cites] Epidemiology. 2010 Jan;21(1):128-38 [20010215.001]
  • [Cites] Ultrasound Obstet Gynecol. 2000 Oct;16(5):500-5 [11169340.001]
  • (PMID = 20961457.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2988009
  •  go-up   go-down


8. Wertel I, Polak G, Bednarek W, Barczyński B, Roliński J, Kotarski J: Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer. Cytometry B Clin Cytom; 2008 Jul;74(4):251-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell subsets in the peritoneal fluid and peripheral blood of women suffering from ovarian cancer.
  • BACKGROUND: Evaluation of immature myeloid and lymphoid dendritic cells (DCs) in the peritoneal fluid (PF) and peripheral blood (PB) mononuclears of women with ovarian carcinoma (n = 47) and benign ovarian tumors (n = 37).
  • RESULTS: The percentage of PF myeloid DC (MDC) in mononuclears was significantly lower in patients with ovarian cancer in comparison to the group of nonmalignant ovarian tumors (0.65% and 6.95%).
  • The percentage of PF lymphoid DCs (LDCs) was higher in patients with ovarian cancer than in the reference group (0.64% and 0.09%).
  • In women suffering from ovarian cancer the percentage of both MDCs and LDCs was higher in the PF than in the PB.
  • In women with ovarian cancer, PF MDCs/LDCs ratio was lower in comparison to patients with serous cystadenoma.
  • LDC subsets may have influence on the local immune response in the PF of women with malignant tumors of the ovary. (c) 2008 Clinical Cytometry Society.
  • [MeSH-major] Ascitic Fluid / cytology. Dendritic Cells / metabolism. Ovarian Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystadenoma, Serous / immunology. Cystadenoma, Serous / pathology. Disease Progression. Female. Flow Cytometry. Humans. Leukocytes, Mononuclear / immunology. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18302193.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Bar JK, Słomska I, Rabczyńki J, Noga L, Gryboś M: Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors. Int J Gynecol Cancer; 2009 Nov;19(8):1322-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p53 protein phosphorylated at serine 20 and serine 392 in malignant and benign ovarian neoplasms: correlation with clinicopathological parameters of tumors.
  • The study investigated the expression of p53 protein phosphorylated at serine 20 (Ser20) and Ser392 and the association between clinicopathological parameters of ovarian neoplasms with respect to p53 protein overexpression.
  • METHODS: p53 protein expression was evaluated on tissues from malignant and benign ovarian tumors.
  • RESULTS: The correlation between p53 protein overexpression and p53-Ser392 phosphorylation was found in ovarian carcinomas (P = 0.001, r = +0.27).
  • In the total group of ovarian carcinomas, significant differences were observed in p53 protein overexpression between well (G1) and poor (G3) tumor grades (P = 0.005) and between serous and endometrioid types of tumor (P = 0.04), whereas p53-Ser20 phosphorylation was associated with advanced International Federation of Gynecology and Obstetrics stage (P = 0.004) and high tumor grade (P = 0.02).
  • In p53-positive ovarian carcinomas, p53-Ser392 phosphorylation was associated with advanced tumor stage (P = 0.02) and high tumor grade (P = 0.049).
  • p53-Ser20 phosphorylation was associated with low tumor grade of p53-positive ovarian carcinomas (P = 0.02) and with high tumor grade of p53-negative ovarian carcinomas (P = 0.02).
  • CONCLUSIONS: These results revealed that p53 phosphorylation at Ser20 and Ser392 is an early event in ovarian tumor development.
  • The authors suggest that the expression of p53 protein phosphorylated at Ser20 and Ser392 in ovarian carcinomas determines their individual clinical features depending on p53 protein status and may be useful biological biomarkers characterizing their behavior.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Serous / metabolism. Endometrial Neoplasms / metabolism. Neoplasms / metabolism. Ovarian Neoplasms / metabolism. Serine / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. L-SERINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009884.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 452VLY9402 / Serine
  •  go-up   go-down


10. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
  • METHODS: Ovarian cancer cell lines and snap-frozen archived tissue samples were sonicated and cathepsin activities were assayed fluorometrically with cathepsin-specific peptide substrates in combination with specific inhibitors.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsin D / metabolism. Ovarian Neoplasms / enzymology. Ovary / enzymology
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


11. Mrochem J, Sodowski K, Deja R, Walaszek-Gruszka A, Wojcieszek A, Kołosza Z, Chmura A, Czernik E, Masłyk B, Bartnik W, Cnota W: [Evaluation of selected serum protein markers as early detectors of ovarian cancer]. Ginekol Pol; 2008 Apr;79(4):271-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
  • OBJECTIVE: an attempt to determine the value of the simultaneous quantization of osteopontin (OPN), insulin-growth factor II (IGF II), leptin, prolactin and CA 125 for early detection of ovarian cancer.
  • MATERIALS AND METHODS: Prospective study of 69 women including: 15 females with ovarian cancer; 33 females with benign ovarian neoplasm; 21 disease-free females; The levels of IGF II, prolactin, leptin and CA 125 were determined in serum, while the level of OPN was checked in plasma.
  • RESULTS: The concentrations of IGF II, leptin and prolactin do not let us distinguish among disease-free females, females with ovarian cancer and those with benign ovarian neoplasms on the basis of biochemical markers.
  • The comparison of OPN and CA 125 levels showed significant differences in the concentrations of the biomarkers between disease-free females and females with ovarian cancer, as well as between females with benign ovarian neoplasms and females with ovarian cancer.
  • The ROC curves for two groups: disease-free females and females with ovarian cancer, proved the diagnostic value of OPN and CA 125.
  • CONCLUSIONS: The simultaneous quantization of OPN, IGF II leptin and prolactin has not been proved useful for the early detection of ovarian cancer.
  • Statistically significant increase of OPN & CA 125 levels was noted in case of women with ovarian cancer diagnosed through microscopic examination.
  • Quantization of OPN may have an additional value for treatment monitoring of women diagnosed with ovarian cancer but with concentration of CA 125 within the reference value.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. CA-125 Antigen / blood. Early Diagnosis. Female. Humans. Insulin-Like Growth Factor II / analysis. Leptin / blood. Middle Aged. Osteopontin / blood. Poland. Prolactin / blood. Prospective Studies. ROC Curve. Reference Values. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592865.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / IGF2 protein, human; 0 / Leptin; 106441-73-0 / Osteopontin; 67763-97-7 / Insulin-Like Growth Factor II; 9002-62-4 / Prolactin
  •  go-up   go-down


12. Tomsová M, Krepinská E, Spacek J: [Sclerosing stromal tumor--a rare benign ovarian neoplasm]. Ceska Gynekol; 2008 Jun;73(3):188-91
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing stromal tumor--a rare benign ovarian neoplasm].
  • [Transliterated title] Sklerozující stromální tumor--vzácný gonadostromální nádor ovaria.
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of the sex cord-stromal category occurring predominantly in young women (usually younger than 30 years of age).
  • Histologically, the tumor is characterized by cellular heterogenity, prominent vascularisation, and a pseudolobular appearance composed of cellular and hypocellular areas.
  • We report a case of the ovarian SST in a 17-year-old girl.
  • Clinical, microscopic, immunohistochemical, ultrastructural findings and differential diagnosis are disscussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646673.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


13. Markowska A, Ziółkowska A, Jaszczyńska-Nowinka K, Madry R, Malendowicz LK: Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers. Eur J Gynaecol Oncol; 2009;30(5):518-22
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated blood plasma concentrations of active ghrelin and obestatin in benign ovarian neoplasms and ovarian cancers.
  • The two peptides are secreted into the blood but circulating levels of these peptides have not been assessed in women with ovarian tumours.
  • Therefore, the purpose of this study was to evaluate peripheral blood concentrations of active and total ghrelin and obestatin in patients with benign ovarian tumours and those with ovarian cancer.
  • The studies were conducted on 22 patients operated due to benign ovarian tumours, and 31 patients operated due to ovarian cancer.
  • Both in women with benign ovarian tumours and those with ovarian cancer blood concentrations of active ghrelin and obestatin were higher than in the control group (active ghrelin: 90 +/- 4, 84 +/- 4 and 56 +/- 9 pg/ml, respectively, obestatin: 660 +/- 36; 630 +/- 30 and 538 +/- 31 ng/ml (x +/- SE), respectively).
  • The alterations resulted in increased values of active to total ghrelin concentration ratio in the peripheral blood of patients with benign ovarian tumours or with ovarian cancer (0.79 +/- 0.02 and 0.93 +/- 0.05, respectively vs 0.58 +/- 0.02 in the control group).
  • Due to the absence of any convincing proof for the presence of a functional GHS-R-1a receptor for ghrelin in human ovaries it did not seem probable that the observed elevated levels of active ghrelin and obestatin were directly linked to development of ovarian tumours.
  • [MeSH-major] Ghrelin / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / pathology. Peptide Hormones / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19899406.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Peptide Hormones; 0 / obestatin, human
  •  go-up   go-down


14. Zaman S, Majid S, Hussain M, Chughtai O, Mahboob J, Chughtai S: A retrospective study of ovarian tumours and tumour-like lesions. J Ayub Med Coll Abbottabad; 2010 Jan-Mar;22(1):104-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective study of ovarian tumours and tumour-like lesions.
  • Objective of the study was to determine the nature of various ovarian lesions and to ascertain the frequency and distribution of the various non-neoplastic and neoplastic lesions.
  • METHODS: The study was a retrospective review of all cases of ovarian cancer, benign ovarian neoplasm and functional ovarian cysts received during Jan-Dec 2008 at Chughtai's Lahore Laboratory.
  • Among the neoplastic tumours 78.70% were benign and 21.29% were malignant.
  • Benign serous cysts were the commonest benign tumour followed by mature cystic teratoma and mucinous cyst.
  • Serous cystadenocarcinoma was the commonest malignant tumour followed closely by endometrioid carcinoma and granulosa cell tumour.
  • Krukenberg tumour, tumour metastatic to ovaries and non-Hodgkins lymphoma was also diagnosed during this period.
  • CONCLUSION: The morphologic diversity of ovarian masses poses many challenges.
  • A specific diagnosis can usually be made by evaluating routinely stained slides but sometimes immunohistochemistry is required in difficult cases.
  • [MeSH-major] Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Middle Aged. Ovarian Cysts / epidemiology. Ovarian Cysts / pathology. Pakistan / epidemiology. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21409917.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


15. Zou JF, Li JY, Wu XW, Chen SY: [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec;26(12):1252-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic].
  • AIM: To investigate the effects of different anesthesia and analgesia on erythrocyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • METHODS: 120 patients with ovarian benign tumor treated by laparoscopic therapeutic were randomly divided into two groups with 60 cases each.In group A, patients received general anesthesia eombined with thoracic epidural anesthesia during surgery, patients in group B received general anesthesia.
  • CONCLUSION: Anesthesia may harm on erythroeyte immune function of patients with ovarian benign tumor treated by laparoscopic therapeutic.
  • [MeSH-major] Analgesia / adverse effects. Anesthesia / adverse effects. Erythrocytes / immunology. Laparoscopy. Ovarian Neoplasms / immunology. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Anesthesia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21138693.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  •  go-up   go-down


16. Mülayim B, Gürakan H, Dagli V, Mülayim S, Aydin O, Akkaya H: Unaware of a giant serous cyst adenoma: a case report. Arch Gynecol Obstet; 2006 Mar;273(6):381-3
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of 36-year-old nonmarried virgin woman presenting a giant ovarian serous cyst adenoma weighing 9.5 kg is reported here.
  • Ovarian neoplasms may be divided by origin cell type into three main groups: epithelial, stromal and germ cell.
  • Taken as a group, the epithelial tumors are by far the most common type.
  • The single most common benign ovarian neoplasm is the benign cystic teratoma; however, according to some studies it is serous cyst adenoma.
  • At laparotomy, a giant, totally cystic, vascularized and smooth mass attached to the right ovary was encountered, lying between the symphysis and the xiphoid.
  • This is the largest ovarian cyst that ever reported from our hospital and one of the largest among the reported cases in the literature.
  • [MeSH-major] Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16249904.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Bunyavejchevin S, Phupong V: Laparoscopic surgery for presumed benign ovarian tumor during pregnancy. Cochrane Database Syst Rev; 2006;(4):CD005459
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic surgery for presumed benign ovarian tumor during pregnancy.
  • BACKGROUND: The surgical management of ovarian tumors in pregnancy is similar to that of non-pregnant women.
  • The procedures include resection of the tumor (enucleation), removal of an ovary or ovaries (oophorectomy), or surgical excision of the fallopian tube and ovary (salpingo-oophorectomy).
  • OBJECTIVES: To compare the effects of using laparoscopic surgery for benign ovarian tumor during pregnancy on maternal and fetal health and the use of healthcare resources.
  • SELECTION CRITERIA: Randomized controlled trials with reported data that compared outcomes of laparoscopic surgery for benign ovarian tumor in pregnancy to conventional laparotomy technique.
  • AUTHORS' CONCLUSIONS: The practice of laparoscopic surgery for benign ovarian tumour during pregnancy is associated with benefits and harms.
  • The available case series studies of laparoscopic surgery for benign ovarian tumour during pregnancy provide limited insight into the potential benefits and harms associated with this new surgical technique in pregnancy.
  • Randomized controlled trials are required to provide the most reliable evidence regarding the benefits and harms of laparoscopic surgery for benign ovarian tumour during pregnancy.
  • [MeSH-major] Laparoscopy. Ovarian Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2013;1:CD005459 [23440802.001]
  • (PMID = 17054259.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 26
  •  go-up   go-down


18. Popovska S, Popovski K, Gorchev G, Marinov E: [Sclerosing stromal ovarial tumor--a case report and review]. Akush Ginekol (Sofiia); 2005;44(4):42-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Sclerosing stromal ovarial tumor--a case report and review].
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm of stromal origin with less than 100 cases reported in the literature.
  • Unlike the other stromal tumors, the comas and fibromas, which tend to occur in the fifth and sixth decades, sclerosing stromal tumors predominantly affect females in the second and third decades.
  • Several unique histologic features including pseudolobulation, sclerosis and prominent vascularity of the tumor are clearly reflected at ultrasonography.
  • We present a case of SST of the ovary in a 26-year-old female, and describe the ultrasound findings with pathologic correlation.
  • [MeSH-major] Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16028379.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


19. Hayashi M, Shibazaki M, Sohma R, Inaba N: Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors. Am J Med Sci; 2006 Oct;332(4):181-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of histologic type on levels of macrophage colony-stimulating factor in liquid contents of benign ovarian tumors.
  • BACKGROUND: Normal ovarian tissue is rich in cytokines.
  • Cytokines are important in the physiology of ovarian function.
  • Most of the same cytokines that are found in normal ovarian tissue are also found in association with benign and malignant tumors in contrast to their functions in normal tissues.
  • Thus, we measured macrophage colony-stimulating factor (M-CSF) levels in the liquid contents of benign ovarian tumors--serous cystadenoma, mucinous cystadenoma, and mature cystic teratoma--and investigated whether M-CSF levels were associated with the histologic type of the ovarian tumors.
  • METHODS: We enrolled 65 patients, 52 with benign ovarian tumor and 13 in the early postmenopausal period with symptoms of a menopausal disorder.
  • Among the 52 patients with benign ovarian tumor, 16 had serous cystadenoma, 21 had mucinous cystadenoma, and 15 had mature cystic teratoma.
  • Immediately after surgery, the liquid content was drawn from the ovarian tumor, then centrifuged, and the separated supernatant was stored at -30 degrees C.
  • The serum M-CSF levels were 308 to 499 U/mL in patients with benign ovarian tumor.
  • CONCLUSIONS: Elevation of levels of M-CSF varies according to histologic type in benign ovarian tumors.
  • [MeSH-major] Extracellular Fluid / metabolism. Macrophage Colony-Stimulating Factor / metabolism. Neoplasm Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17031243.001).
  • [ISSN] 0002-9629
  • [Journal-full-title] The American journal of the medical sciences
  • [ISO-abbreviation] Am. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 81627-83-0 / Macrophage Colony-Stimulating Factor
  •  go-up   go-down


20. Wilczyńqski JR, Nowińska A, Szpakowski M, Nowak M, Szpakowski A, Władziński J, Kufelnicka M, Znojek W: [Laparoscopic treatment of benign ovarian tumors]. Ginekol Pol; 2006 Jan;77(1):40-7
MedlinePlus Health Information. consumer health - Women's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic treatment of benign ovarian tumors].
  • BACKGROUND: laparoscopic surgery is one of the most common procedures performed in the presence of benign ovarian tumor.
  • THE AIM OF THE STUDY: The purpose of our study was to analyze clinical findings, operative procedures, size and histopathologic type of tumors, time of hospitalization and surgical complications.
  • MATERIAL AND METHODS: 102 female patients operated for benign adnexal masses by laparoscopic approach, in 3rd Department of Gynecology and Obstetrics, University of Medicine, Lódź, between 2001-2004.
  • RESULTS: the most frequent laparoscopic procedure was excision of the tumor (59.8%), and the most common histopathologic type was teratoma adultum (25%), endometroid cyst (21.1%) and serous cyst (20.2%), of 5-7 cm median size.
  • CONCLUSIONS: in the case of benign ovarian tumor laparoscopy is recommended procedure due to sparing ovarian function by small tissue traumatisation, shorter time of hospitalization, faster return to the health and low risk of complications.
  • Because of the possibility of encountering an unexpected ovarian malignancy, the laparoscopy should be executed only in the centers where the intraoperative histopathologic examination is a routine procedure.
  • [MeSH-major] Laparoscopy / methods. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery. Women's Health

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736959.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


21. Daneshbod Y, Daneshbod K, Rasekhi AR, Mosayebi Z, Negahban S, Hodjati SR, Bedayat GR, Ganjei-Azar P: Cytologic differentiation of struma ovarii from other ovarian neoplasms. Acta Cytol; 2008 Jan-Feb;52(1):72-6
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic differentiation of struma ovarii from other ovarian neoplasms.
  • OBJECTIVE: To present the cytologic findings of struma ovarii and value of cytology and immunocytochemistry (ICC) using thyroglobulin (TGB) and thyroid transcription factor-1 (TTF-1) in evaluation of this unusual ovarian neoplasm, together with the diagnostic pitfalls.
  • RESULTS: The cases were divided in to 3 groups: group 1--diagnosis of struma ovarii was made by cytology and confirmed by ICC (1 case); group 2--diagnosis was suggestive on cytology or cell block and confirmed by ICC staining (4 cases); group 3--on cytologic diagnosis indistinguishable from other cystic ovarian neoplasms (2 cases).
  • Cytologic findings were typically colloid with mosaic pattern, follicles, follicular cells only, sheets of follicular cells, both colloid and follicular cells, proteinaceous background or degenerated epithelial cells indistinguishable from other cystic ovarian neoplasms.
  • CONCLUSION: Cytologic findings of struma ovarii are distinct enough to be suggested intraoperatively, and ICC for TGB or TTF-1 is a valuable tool for preoperative fine needle aspiration biopsy and intraoperative diagnosis of this benign ovarian neoplasm.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Ovarian Neoplasms / diagnosis. Struma Ovarii / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Nuclear Proteins / metabolism. Thyroglobulin / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323278.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


22. Medeiros LR, Rosa DD, Bozzetti MC, Fachel JM, Furness S, Garry R, Rosa MI, Stein AT: Laparoscopy versus laparotomy for benign ovarian tumour. Cochrane Database Syst Rev; 2009;(2):CD004751
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy versus laparotomy for benign ovarian tumour.
  • BACKGROUND: Over the last 10 years laparoscopy and minilaparotomy have become increasingly common approaches for the surgical removal of benign ovarian tumours.
  • However, in the event that a tumour is found to be malignant, laparotomy is the appropriate procedure.
  • OBJECTIVES: To determine the benefits, harms, and cost of laparoscopy or minilaparotomy compared with laparotomy in women with benign ovarian tumours.
  • SELECTION CRITERIA: All randomised controlled trials comparing either laparoscopy or minilaparotomy with laparotomy for benign ovarian tumours.
  • AUTHORS' CONCLUSIONS: In women undergoing surgery for benign ovarian tumours, laparoscopy was associated with a reduction in fever, urinary tract infection, postoperative complications, postoperative pain, number of days in hospital, and total cost.
  • [MeSH-major] Laparoscopy. Laparotomy. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(3):CD004751 [16034946.001]
  • (PMID = 19370607.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 78
  •  go-up   go-down


23. Barwijuk AJ, Bonarek-Sztaba J: [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors]. Ginekol Pol; 2006 Jun;77(6):450-1, 454-7
Hazardous Substances Data Bank. Carbon dioxide .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of gas and gasless laparoscopy in the treatment of benign ovarian tumors].
  • OBJECTIVES: The aim of the study was to compare the outcomes of the gas and gasless laparoscopy in the treatment of benign ovarian tumors.
  • An ovarian tumor considered to be benign was the indication to operation.
  • Those assessments revealed that all tumors had been benign.
  • [MeSH-major] Laparoscopy / methods. Ovarian Neoplasms / surgery. Pneumoperitoneum, Artificial / methods

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964696.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 142M471B3J / Carbon Dioxide
  •  go-up   go-down


24. Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, Bae DS: Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors. Int J Gynaecol Obstet; 2010 Jan;108(1):12-5
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors influencing the choice of laparoscopy or laparotomy in pregnant women with presumptive benign ovarian tumors.
  • OBJECTIVE: To evaluate the factors associated with physicians' choice of laparotomy or laparoscopy in pregnant women with presumptive benign ovarian tumors.
  • METHODS: Retrospective comparative analysis of pregnant women who underwent laparotomy or laparoscopy for ovarian tumors and who delivered at Samsung Medical Center, Seoul, Korea, between July 1995 and April 2008.
  • RESULTS: Univariate analysis revealed that the following factors had a significant or a borderline significant association with the choice of operation type: maternal age (P=0.044); surgeon type (professor vs clinical fellow; P=0.094); tumor mass size (P=0.081); gestational age (P=0.035); and time since surgery (P<0.001).
  • Multivariate analysis showed that tumor size (P=0.030), gestational age (P=0.027), and time since surgery (P=0.004) were independent factors associated with physicians' choice of laparoscopy or laparotomy for the management of presumptive benign ovarian tumors during pregnancy.
  • CONCLUSIONS: In the latter years of the present study, physicians at the study center preferred the laparoscopic approach for managing presumptive benign ovarian tumors during pregnancy.
  • Furthermore, they preferred this approach to laparotomy for pregnancies at a relatively early gestational age and for treating small tumors.
  • [MeSH-major] Laparoscopy / methods. Laparotomy / methods. Ovarian Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19892330.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Stanković ZB, Djukić MK, Sedlecki K, Djuricić S, Lukac BJ, Mazibrada I: Rapidly growing bilateral ovarian cystadenoma in a 6-year-old girl: case report and literature review. J Pediatr Adolesc Gynecol; 2006 Feb;19(1):35-8
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for ovarian cystadenoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapidly growing bilateral ovarian cystadenoma in a 6-year-old girl: case report and literature review.
  • BACKGROUND: Benign ovarian neoplasms originating from epithelial tissue are common tumors in adult women.
  • Repeated ultrasonographic examinations revealed bilateral, cystic, rapidly growing ovarian masses.
  • Cysts were surgically removed, with preservation of normal ovarian tissue, and histopathologic findings showed a serous cystadenoma of both ovaries.
  • [MeSH-major] Cystadenoma, Serous / ultrasonography. Ovarian Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16472727.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


26. Yan XJ, Tian Y, Wang C, Wang XL, Di JM, Cheng JX: [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jul;40(4):639-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expressions and clinical significance of IGFBP-2, -3 in both serum and tumor tissues in patients with epithelial ovarian cancer].
  • OBJECTIVE: To explore the serum levels of IGFBP-2, -3 and their proper roles in the regulation of IGF-II bioavailability in patients with ovarian tumor, and to investigate the correlation between the expressions of IGFBP-2 and IGFBP-3 in ovarian tumor tissues and related clinicopathological characteristics.
  • METHODS: Serum levels of IGFBP-2, -3 and big/mature IGF-II were measured by Western ligand blot (WLB) and Western blot (WB) in patients with ovarian tumor (10 cases of benign tumor, 6 cases of borderline tumor and 10 cases of malignant tumor) and 10 cases of normal control.
  • The expressions of IGFBP-2 and IGFBP-3 were examined in 39 specimens of ovarian tumor (8 cases of benign tumor, 8 cases of borderline tumor and 23 cases of malignant tumor) and 4 cases of normal ovarian tissues by immunohistochemical staining.
  • RESULTS: The serum levels of both big and mature IGF-II in epithelial ovarian cancer (ovarian cancer) patients were significantly decreased compared with those of normal control and benign and borderline tumor (P<0.001 or P<0.01).
  • The increased serum level of IGFBP-2 and decreased IGFBP-3 level were observed in patients with malignant ovarian tumors by comparing with those of patients with normal controls, benign and borderline tumor (P<0.001 or P<0.01).
  • The expression of IGFBP-2 was significantly higher in malignant ovarian tumor tissues than those in normal control and benign ovarian tumors tissues (P<0.0001, P<0.001, and the expression of IGFBP-3 decreased significantly in lower differentiated ovarian cancer tissues compared with that in high and moderate differentiated ovarian cancer tissues (P<0. 05).
  • CONCLUION: IGFBP-2 predominantly presents in the circulation of malignant patients in contrast to IGFBP-3, which may result in altered bioavailability of IGF-II in ovarian cancer, leading to the progress of tumor.
  • The serum levels of both IGFBP-2 and IGFBP-3 and their expressions in tumor tissues are correlated with the clinicopathological characteristics of ovarian cancer patients.
  • Our findings suggest that the presence of new mechanisms in the regulation of IGF-II bioavailability, and provide the evidence for the possibility to use IGFBP-2/IGFBP-3 as biological markers in diagnosis and prognosis of ovarian cancer.
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 2 / blood. Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor II / analysis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19764562.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


27. Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, Lee K: Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother; 2009 Jan;58(1):15-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment.
  • PURPOSE: Inflammatory cells can both suppress and stimulate tumor growth, and the influence of inflammatory cells on clinical outcome has been the focus of many studies.
  • The purpose of this study was to evaluate the effectiveness of the neutrophil to lymphocyte ratio (NLR), a measure of the systemic inflammatory response, as an additional discriminative biomarker in epithelial ovarian cancer and to determine whether it predicts survival and recurrence.
  • METHODS: We studied 192 patients with epithelial ovarian cancer, 173 with benign ovarian tumors, 229 with benign gynecologic disease, and 405 healthy controls.
  • In epithelial ovarian cancer, the diagnostic usefulness of NLR, in combination with CA125, was evaluated.
  • RESULTS: Preoperative NLR in ovarian cancer subjects (mean 6.02) was significantly higher than that in benign ovarian tumor subjects (mean 2.57), benign gynecologic disease subjects (mean 2.55), and healthy controls (mean 1.98) (P < 0.001).
  • The sensitivity and specificity of NLR in detecting ovarian cancer was 66.1% (95% CI, 59.52-72.68%) and 82.7% (95% CI, 79.02-86.38%), respectively (cutoff value: 2.60).
  • In early stage ovarian cancer, CA125 was not elevated in 19 out of 49 patients.
  • CONCLUSIONS: Our findings provide evidence for the association between NLR and epithelial ovarian cancer.
  • Preoperative NLR, in combination with CA125, may represent a simple and cost-effective method of identifying ovarian cancers, and an elevated NLR may predict an adverse outcome in ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor. Lymphocyte Count. Neoplasms, Glandular and Epithelial / pathology. Neutrophils / cytology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18414853.001).
  • [ISSN] 1432-0851
  • [Journal-full-title] Cancer immunology, immunotherapy : CII
  • [ISO-abbreviation] Cancer Immunol. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


28. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, Frezza EE: Survivin expression in ovarian cancer. Exp Oncol; 2007 Jun;29(2):121-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin expression in ovarian cancer.
  • AIM: To examine the expression of survivin in benign ovarian tumors, ovarian carcinomas of different stages.
  • METHODS: We screened the expression of survivin mRNA by reverse transcription polymerase chain reaction in 114 ovarian tissue samples.
  • RESULTS: No survivin mRNA was expressed in all normal ovarian specimens, while it appeared in 73% of ovarian carcinomas, 47% of borderline ovarian carcinomas and 19% of benign ovarian tumors.
  • In tissues with positive expression of survivin, we also found that mean survivin mRNA expression levels were higher in ovarian carcinomas than that in benign ovarian tumors and borderline ovarian carcinoma tissues (P < 0.001).
  • Among ovarian carcinomas, the high survivin mRNA expression levels correlated with the clinical stages, differentiation grade, lymph node metastasis, but not - with ascites and histological type.
  • CONCLUSION: Our study suggest that survivin is associated with progression of ovarian carcinoma.
  • [MeSH-major] Cystadenoma, Mucinous / metabolism. Cystadenoma, Serous / metabolism. Neoplasm Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Carcinoma / metabolism. Carcinoma / pathology. Disease Progression. Female. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704744.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


29. Qiao YH, Cheng J, Guo RX: [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer]. Zhonghua Fu Chan Ke Za Zhi; 2007 May;42(5):325-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of phosphorylated protein kinase B and PTEN protein in ovarian epithelial cancer].
  • OBJECTIVE: To analyze the expression of phosphorylated protein kinase B (pAKT) and PTEN protein in ovarian epithelial cancer and to investigate the correlations between their expression and prognosis of ovarian epithelial cancers.
  • METHODS: Expression of pAKT and PTEN in 12 normal ovarian tissues, 20 benign tumors, 12 borderline tumors and 80 cases of ovarian epithelial cancers were detected by immunohistochemical method, and their correlations were analyzed.
  • RESULTS: The positive expression of pAKT in normal ovarian and benign tumor tissues were significantly lower than that in ovarian epithelial cancers (8%, 10% vs 55%; P < 0.01), respectively.
  • However, loss of PTEN expression in ovarian epithelial cancers was significantly higher than that in normal ovarian and benign tumor tissues, and the positive rate of PTEN expression were respectively, 45%, 100%, and 80% (P < 0.01).
  • In ovarian cancers, a negative correlation between expression of pAKT and PTEN was observed (r = -0.444, P < 0.01).
  • CONCLUSIONS: The overexpression of pAKT and absence of PTEN are related to ovarian carcinogenesis and development.
  • Loss of PTEN expression is the independent risk factor of poor prognosis in patients with ovarian epithelial cancers.
  • [MeSH-major] Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis. Proto-Oncogene Proteins c-akt / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Ovary / metabolism. Ovary / pathology. Phosphorylation. Prognosis. Survival Analysis. Tumor Suppressor Proteins / biosynthesis


30. Coronado Martín PJ, Fasero Laiz M, García Santos J, Ramírez Mena M, Vidart Aragón JA: [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer]. Med Clin (Barc); 2007 Jan 13;128(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
  • [Transliterated title] Grado de expresión y valor pronóstico de las proteínas p53 y HER2/neu en el tejido ovárico benigno y en el cáncer de ovario.
  • BACKGROUND AND OBJECTIVE: To investigate the prognostic value of p53 and HER2/neu overexpression in epithelial ovarian cancer (EOC).
  • PATIENTS AND METHOD: p53 and HER2/neu immunostaining were performed in 198 tissue samples, 124 EOC, 44 benign ovarian tumors and 30 normal ovaries.
  • RESULTS: Neither p53 nor HER2/neu overexpression was seen in the benign ovarian tumors.
  • HER2/neu immunostaining was observed in one normal ovary.
  • [MeSH-major] Cystadenoma, Mucinous / genetics. Cystadenoma, Serous / genetics. Ovarian Neoplasms / genetics. Receptor, ErbB-2 / genetics. Teratoma / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Aged. Biomarkers, Tumor. Confidence Intervals. Endometriosis / genetics. Endometriosis / pathology. Endometriosis / surgery. Female. Follow-Up Studies. Genes, p53. Humans. Immunohistochemistry. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Neoplasm Staging. Ovarian Diseases / genetics. Ovarian Diseases / pathology. Ovarian Diseases / surgery. Prognosis. Proportional Hazards Models. Risk. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17266884.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


31. Zhang S, Lin QD, DI W: Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):522-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1.
  • Expression of BRMS1 messenger RNA (mRNA) in multitissue including normal prostate, ovarian, testis, and colon has been detected by northern blot analysis.
  • We hypothesize that the role of BRMS1 in tumor progression may not be limited to breast cancer and melanoma.
  • We previously found that BRMS1 mRNA levels in primary ovarian epithelial carcinomas were significantly lower than that in normal ovarian and benign tumors (P < 0.05), and statistical analysis of BRMS1 mRNA levels revealed that BRMS1 mRNA levels were significantly higher in early tumor stages (I, II) compared with advanced tumor stages (III, IV) in which lymph node or distant metastases were present (P < 0.01).
  • Our data showed that reduced BRMS1 mRNA seems to influence ovarian carcinoma metastatic ability.
  • Therefore, we transfected BRMS1 plasmid into highly malignant ovarian carcinoma cell line, HO-8910PM, and examined cell biologic behaviors including proliferation, adhesion, invasion, and metastasis in vitro and in vivo.
  • BRMS1 expression did not alter the proliferation of HO-8910PM cells in vitro and primary tumor formation in vivo.
  • Also, BRMS1 transfectants form significantly less metastatic to organs of peritoneal cavity in orthotopically implanted ovarian tumor nude models.
  • These data suggested that in addition to its already described role in breast cancer and melanoma, BRMS1 functions as a metastasis-suppressor gene in ovarian carcinoma by modifying several metastatic-associated phenotypes, offering a new target for therapeutic intervention.
  • [MeSH-major] Gene Expression Regulation / physiology. Neoplasm Proteins / physiology. Ovarian Neoplasms / prevention & control
  • [MeSH-minor] Animals. Cell Movement. Cell Proliferation. Disease Models, Animal. Down-Regulation. Female. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Invasiveness. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / prevention & control. Neoplasms, Glandular and Epithelial / secondary. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. RNA, Messenger / metabolism. Repressor Proteins. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Tumor Cells, Cultured. Tumor Stem Cell Assay

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681721.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRMS1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Repressor Proteins
  •  go-up   go-down


32. Attia L, Chachia A, Ben Temime R, Bennour G, Makhlouf T, Koubâa A: [Benign ovarian tumors during pregnancy. A review of 26 cases]. Tunis Med; 2008 Jul;86(7):680-4
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign ovarian tumors during pregnancy. A review of 26 cases].
  • [Transliterated title] Tumeurs de l'ovaire au cours de la grossesse: a propos de 26 cas.
  • OBJECTIVE: To identify the particularities of ovarian tumors during pregnancy.
  • METHODS: A retrospective study of 26 patients who underwent surgical treatment for ovarian tumors during pregnancy between January 1993 and December 2005.
  • The circumstances under which the ovarian tumors were discovered consisted of adnexal torsion in 57% of cases, chronic pelvic pain in 15% of cases and at routine ultrasonographic scan in 26% of cases.
  • CONCLUSION: Ovarian tumors during pregnancy are rare.
  • Laparoscopic ovarian cystectomy offers significant advantages with respect to laparotomy for the pregnant patient.
  • [MeSH-major] Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19472731.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Tunisia
  •  go-up   go-down


33. Inai K, Shimizu Y, Kawai K, Tokunaga M, Soda M, Mabuchi K, Land CE, Tokuoka S: A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report. J Radiat Res; 2006 Mar;47(1):49-59
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pathology study of malignant and benign ovarian tumors among atomic-bomb survivors--case series report.
  • The present article describes the series of incident primary ovarian tumors in the Life Span Study (LSS) cohort of the Radiation Effects Research Foundation, with particular emphasis on case ascertainment and characterization of histological features of the tumors.
  • We identified 723 ovarian tumors (260 malignant, 463 benign) in 648 individuals of about 70,000 female LSS subjects; 71 cases had more than one ovarian tumor.
  • We histologically confirmed 601 tumors (182 malignant, 419 benign tumors).
  • The most frequent histological type was common epithelial tumor (90.7% for malignant and 59.7% for benign tumors).
  • The distributions of ovarian tumors by histological type were similar to those from other studies.
  • Among malignancies, the frequency of common epithelial types relative to other tumor types increased with radiation dose (p = 0.02).
  • Among benign tumors, the relative frequency of sex-cord stromal tumors increased with radiation dose (p = 0.04).
  • Within tumor types, there was no consistent pattern of survival by radiation dose.
  • Variations in histological types of ovarian tumors in response to radiation dose, suggested by the case series data need to be followed up by population-based incidence analysis.
  • [MeSH-major] Neoplasms, Radiation-Induced / mortality. Neoplasms, Radiation-Induced / pathology. Nuclear Warfare / statistics & numerical data. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Risk Assessment / methods. Survivors / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16571918.001).
  • [ISSN] 0449-3060
  • [Journal-full-title] Journal of radiation research
  • [ISO-abbreviation] J. Radiat. Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CP / N01-CP-31012; United States / NCI NIH HHS / CP / N01-CP-71015
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Japan
  •  go-up   go-down


34. Wright JD, Powell MA, Mutch DG, Rader JS, Gibb RK, Gao F, Herzog TJ: Relationship of ovarian neoplasms and body mass index. J Reprod Med; 2005 Aug;50(8):595-602
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of ovarian neoplasms and body mass index.
  • OBJECTIVE: To describe the distribution of benign and malignant ovarian neoplasms among overweight and obese women.
  • STUDY DESIGN: A review of patients who presented with a preoperative diagnosis of a pelvic mass between 1996 and 2001 was performed; 1,096 patients were identified.
  • Women with normal body mass indices were more likely to have malignant ovarian tumors (35.2%) than were the overweight (23.9%) and obese (25.8%) women.
  • Conversely, borderline ovarian tumors were less frequent in women with body mass indices of <25 (5.7%) than in the overweight (13.1%) and obese (10.9%) patients.
  • Benign ovarian neoplasms occurred in 20-25% of the women.
  • CONCLUSION: Significant differences exist in the distribution of ovarian neoplasms among women with different body mass indices.
  • Obese women are more likely to have ovarian tumors of low malignant potential, while women with normal body mass indices more commonly have invasive ovarian tumors.
  • [MeSH-major] Body Mass Index. Obesity / complications. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Body Weight / physiology. Child. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Ovarian Cysts / diagnosis. Ovarian Cysts / pathology. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16220765.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Sedláková I, Vávrová J, Tosner J, Hanousek L: Lysophosphatidic acid: an ovarian cancer marker. Eur J Gynaecol Oncol; 2008;29(5):511-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lysophosphatidic acid: an ovarian cancer marker.
  • OBJECTIVE: To determine whether lysophosphatidic acid (LPA) can serve as an ovarian cancer marker, we compared plasma LPA levels in ovarian cancer patients, in women with no ovarian pathology, and in women with benign ovarian tumors.
  • METHOD: Capillary electrophoresis with indirect ultraviolet detection was used to analyze the plasma LPA levels of 133 patients (60 patients with ovarian cancer, 43 women without ovarian pathologies and 30 patients with benign ovarian tumors) during a three-year period.
  • RESULTS: Patients with ovarian cancer had a significantly higher plasma LPA level (n=60, median (med) 16.99 micromnol/l, range 4.53-43.21 micromol/l) compared with controls with no ovarian pathology (n=43, med 2.92 micromol/l, range 0.94-22.93 micromnol/l) and patients with benign ovarian tumor (n=30, med 7.73 micromol/l, range 1.12-28.84 micromol/l) (p < 0.001).
  • We found that plasma LPA levels were associated with the International Federation of Gynecology and Obstetrics (FIGO) stage and ovarian cancer histological type.
  • Patients with endometrial ovarian cancer had significantly higher plasma LPA levels in comparison with other histological types of epithelial ovarian carcinoma.
  • CONCLUSION: The plasma LPA level can be a useful marker for ovarian cancer, particularly in the early stages of disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Lysophospholipids / blood. Ovarian Neoplasms / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051824.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lysophospholipids; 22002-87-5 / lysophosphatidic acid
  •  go-up   go-down


36. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol; 2008 Feb;108(2):402-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
  • OBJECTIVES: The CA125 tumor marker is used to help predict the presence of ovarian cancer in patients with an adnexal mass.
  • Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125.
  • Of these, 233 patients were eligible for analysis with 67 invasive epithelial ovarian cancers and 166 benign ovarian neoplasms.
  • Mean values for all marker levels except Her2 differed significantly between patients with benign masses and cancer.
  • CONCLUSIONS: As a single tumor marker, HE4 had the highest sensitivity for detecting ovarian cancer, especially Stage I disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / urine. Ovarian Neoplasms / blood. Ovarian Neoplasms / urine. Pelvic Neoplasms / blood. Pelvic Neoplasms / urine


37. Serin IS, Tanriverdi F, Ata CD, Akalin H, Ozcelik B, Ozkul Y, Kelestimur F: GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2010 Mar;149(1):92-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GnRH-II mRNA expression in tumor tissue and peripheral blood mononuclear cells (PBMCs) in patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To investigate the expression of the second form of GnRH (GnRH-II) in tumor tissue and peripheral blood mononuclear cells (PBMCs) in malignant and benign ovarian tumors in humans.
  • STUDY DESIGN: Sixty-six women were studied: 24 with epithelial ovarian carcinomas, 22 with benign ovarian tumors and 20 in the control group undergoing surgery.
  • Malignant, benign and normal ovarian tissue and PBMCs were obtained for measurement of GnRH-II mRNA levels using quantitative real-time RT-PCR.
  • RESULT(S): The expression of GnRH-II was found to be 1.5 times higher in malignant ovarian tumors compared with benign ovarian tumors and the control group in post-menopausal patients (P<0.01).
  • In the post-menopausal patient group with malignant ovarian tumors, there were significant positive correlations between serum FSH level and ovarian tissue GnRH-II mRNA expression (r=0.68; P=0.03), and serum LH level and ovarian tissue GnRH-II mRNA expression (r=0.71; P=0.02).
  • Controls, benign and malignant groups were similar in terms of GnRH-II expression in PBMCs in the pre- and post-menopausal periods.
  • There was no significant correlation between ovarian tissue GnRH-II mRNA expression vs. PBMC GnRH-II mRNA expression in patient and control groups.
  • CONCLUSION(S): We have shown increased GnRH-II expression in human ovarian cancer tissue in post-menopausal women in vivo.
  • Expression of GnRH-II in PBMCs did not reflect the local GnRH-II expression levels in ovarian tissue.
  • These preliminary data suggest that local GnRH-II may participate in the regulation of ovarian tumor growth in post-menopausal women.
  • [MeSH-major] Carcinoma / metabolism. Gonadotropin-Releasing Hormone / analogs & derivatives. Leukocytes, Mononuclear / metabolism. Ovarian Neoplasms / metabolism. Ovary / metabolism
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Postmenopause / genetics. Postmenopause / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20018426.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / RNA, Messenger; 33515-09-2 / Gonadotropin-Releasing Hormone; 91097-16-4 / LHRH, His(5)-Trp(7)-Tyr(8)-
  •  go-up   go-down


38. Green GE, Mortele KJ, Glickman JN, Benson CB: Brenner tumors of the ovary: sonographic and computed tomographic imaging features. J Ultrasound Med; 2006 Oct;25(10):1245-51; quiz 1252-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brenner tumors of the ovary: sonographic and computed tomographic imaging features.
  • OBJECTIVE: The purpose of this study was to describe the sonographic appearance of ovarian Brenner tumors with computed tomographic (CT) correlation.
  • METHODS: Twenty-two female patients (age range, 32-78 years; mean, 58 years) with 25 ovarian Brenner tumors were identified from pathologic records from 1990 to 2005.
  • RESULTS: Tumors ranged in size from 0.3 to 12 cm (mean, 2.5 cm); all were benign.
  • Eight (36%) of 22 patients had a total of 12 associated benign ovarian neoplasms (1 was contralateral); 3 patients had bilateral Brenner tumors.
  • Eight (47%) of 17 tumors were not seen on sonography, and 5 (36%) of 14 were not seen on CT.
  • Of the tumors seen on imaging, most were solid (67% on sonography and 78% on CT).
  • Four tumors appeared at least partially cystic, of which 3 had coexistent cystic ovarian lesions.
  • CONCLUSIONS: Brenner tumors are most often solid neoplasms found incidentally and frequently seen in association with other benign ovarian epithelial neoplasms.
  • [MeSH-major] Brenner Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16998096.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, Young RH: Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol; 2008 Jul;27(3):366-79
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases.
  • Information on ovarian metastasis of carcinoma of the extrahepatic bile ducts and gallbladder is limited.
  • Sixteen examples are reported; 3 primary tumors were hilar cholangiocarcinomas, 5 common bile duct carcinomas, and 8 gallbladder carcinomas.
  • The patients ranged from 21 to 87 years (mean, 59 years); 7 presented to gynecologists with nonspecific pelvic symptoms similar to primary ovarian neoplasms.
  • The primary tumor was identified before the detection of the ovarian lesions in 5 cases, was simultaneously detected with the ovarian metastases in 9, and was diagnosed postoperatively in 2.
  • All but one case had bilateral ovarian involvement.
  • The thirty-one ovarian lesions included twenty-nine grossly abnormal ovaries that were enlarged (range, 3.0-16.5 cm, mean, 9.4 cm) and 2 ovaries with only microscopic involvement.
  • Microscopically, ovarian surface implants were seen in 66%, multinodular growth in 58%, and infiltrative stromal invasion in 81%.
  • Mucinous epithelial differentiation was seen in 81%, sometimes with foci of benign-like or borderline-like epithelium simulating primary ovarian mucinous neoplasia.
  • Signet ring cells were present in sufficient quantity for a diagnosis of Krukenberg tumor in four tumors.
  • Colloid-type carcinoma was observed at least focally in 3 tumors.
  • Although the diagnosis of a metastatic tumor to the ovary is possible in most of the cases based on standard diagnostic criteria, problems in the differential diagnosis may be posed by morphologic patterns that overlap strikingly with primary ovarian neoplasms, benign, borderline, and malignant, as discussed herein.
  • [MeSH-major] Adenocarcinoma / pathology. Bile Duct Neoplasms / pathology. Gallbladder Neoplasms / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580314.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Ahmed N, Latifi A, Riley CB, Findlay JK, Quinn MA: Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer. J Ovarian Res; 2010;3:17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal transcription factor Brn-3a(l) is over expressed in high-grade ovarian carcinomas and tumor cells from ascites of patients with advanced-stage ovarian cancer.
  • OBJECTIVES: In view of the recent association of Brn-3 transcription factors with neuroblastomas, cervical, breast, and prostate cancers we examined the expression of Brn-3a(l) in normal ovaries and in different histological grades of ovarian tumors.
  • The expression of Brn-3a(l) was also evaluated in normal ovarian and cancer cell lines and tumor cells isolated from the ascites of advanced-stage ovarian cancer patients.
  • METHODS: Normal ovaries, benign, borderline, grades 1, 2 and 3 ovarian tumors were analyzed by immunohistochemistry for Brn-3a(l) expression.
  • A total of 46 ovarian specimens were included in the study.
  • Immunofluorescence was used to investigate the expression of Brn-3a in normal ovarian and cancer cell lines.
  • Brn-3a(l) expression was also evaluated by Western blot in tumor cells isolated from ascites of advanced-stage ovarian cancer patients and also in ovarian cancer cell lines.
  • RESULTS: Nearly 12% of normal and benign ovarian tissues and 57% of borderline ovarian tumors were positive for epithelial Brn-3a(l) expression.
  • Stromal staining was higher and it constituted 40% of normal non-cancerous ovaries compared to 50 and 86% in benign and borderline tumors.
  • On the other hand, 85-100% of grades 1, 2 & 3 ovarian tumors demonstrated nuclear and cytoplasmic Brn-3a(l) staining in the epithelium.
  • Stromal staining in grades1, 2 and 3 tumors constituted 71-88% of total staining.
  • Overall, immunoreactive Brn-3a was present in all grades of ovarian tumors.
  • The extent of epithelial and stromal Brn-3a staining was significantly different between the normal and histological grades of tumors (epithelial-chi2 = 41.01, df = 20, P = 0.004, stromal-chi2 = 24.66. df = 15, P = 0.05).
  • The extent of epithelial staining was significantly higher in grades 1 and 2 ovarian tumors compared to normal ovaries and benign ovarian tumors (p < 0.05).
  • In parallel, stromal staining was significantly higher in grade 3 tumors compared to normal ovaries (p < 0.05).
  • In addition, cytoplasmic and nuclear Brn-3a expression was evident in ovarian cancer cell lines while no such expression was observed in SV40 antigen immortalized normal ovarian cell lines.
  • CONCLUSION: These data suggest that like other cancers, Brn-3a(l) expression is enhanced in ovarian tumors and its expression is consistent with its known role in inhibiting apoptosis and enhancing tumorigenesis.
  • Specific targeting of Brn-3a may provide a useful strategy for regulating multiple tumor related genes involved with ovarian carcinomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2010 Aug 1;28(22):3555-61 [20547991.001]
  • [Cites] J Biol Chem. 2010 May 14;285(20):15286-95 [20228055.001]
  • [Cites] Blood. 2010 Mar 18;115(11):2264-73 [19965679.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):134-44 [19088723.001]
  • [Cites] Clin Cancer Res. 2008 Dec 1;14(23):7645-51 [19047089.001]
  • [Cites] Clin Exp Metastasis. 2008;25(6):643-55 [18398687.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1415-24 [18349831.001]
  • [Cites] Cancer Sci. 2008 Mar;99(3):543-52 [18201274.001]
  • [Cites] J Neurochem. 2008 Apr;105(2):425-35 [18086126.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] Endocr Relat Cancer. 2006 Jun;13(2):641-51 [16728589.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2006;9(1):83-91 [16276351.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3072-80 [15833836.001]
  • [Cites] Br J Cancer. 2005 Apr 25;92(8):1475-85 [15798771.001]
  • [Cites] J Biol Chem. 2005 Mar 25;280(12):11851-8 [15598651.001]
  • [Cites] Differentiation. 2004 Apr;72(4):150-61 [15157238.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):428-32 [12432261.001]
  • [Cites] Nucleic Acids Res. 2002 Nov 15;30(22):4872-80 [12433990.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21617-27 [14970234.001]
  • [Cites] Nucleic Acids Res. 1993 Dec 25;21(25):5921-9 [8290353.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):89-94 [8989239.001]
  • [Cites] Genes Dev. 1997 May 15;11(10):1207-25 [9171367.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:62-72 [9474856.001]
  • [Cites] Dev Biol. 1998 May 15;197(2):155-69 [9630743.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16715-22 [9642226.001]
  • [Cites] Int J Biochem Cell Biol. 1998 Nov;30(11):1153-7 [9839440.001]
  • [Cites] J Biol Chem. 1999 Oct 1;274(40):28521-7 [10497216.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6684-91 [10597274.001]
  • [Cites] Int J Gynecol Pathol. 2000 Jan;19(1):7-15 [10638449.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Australas J Dermatol. 1997 Jun;38 Suppl 1:S91-8 [10994482.001]
  • [Cites] Oncogene. 2001 Aug 9;20(35):4899-903 [11521202.001]
  • [Cites] Nucleic Acids Res. 2001 Nov 15;29(22):4530-40 [11713302.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):237-44 [11872628.001]
  • [Cites] Mol Biotechnol. 2002 Oct;22(2):123-7 [12405260.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 12;1579(2-3):207-13 [12427558.001]
  • (PMID = 20670407.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2920243
  •  go-up   go-down


41. Min H, Wei-hong Z: Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma. J Obstet Gynaecol Res; 2009 Oct;35(5):918-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutive activation of signal transducer and activator of transcription 3 in epithelial ovarian carcinoma.
  • AIM: To investigate the expressions of signal transducer and activator of transcription 3 (Stat3) and tyrosine-activated Stat3 (p-Stat3) in epithelial ovarian carcinoma (EOC) and their relationships with clinical pathological parameters or prognosis.
  • METHODS: Immunohistochemical methods were used to detect the expressions of Stat3 and p-Stat3 in EOC, benign ovarian tumors and normal ovarian tissues, after which an analysis of results with clinical pathological or prognosis was given.
  • RESULTS: The expressions of Stat3 and p-Stat3 in EOC were significantly higher than in normal ovarian epithelial tissues or benign ovarian tumor tissues (P < 0.0125) and the expression of Stat3 protein was highly correlated with the expression of p-Stat3 protein (P < 0.01).
  • [MeSH-major] Carcinoma / metabolism. Ovarian Neoplasms / metabolism. STAT3 Transcription Factor / metabolism
  • [MeSH-minor] Adult. Aged. Chi-Square Distribution. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Phosphorylation. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20149042.001).
  • [ISSN] 1447-0756
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / STAT3 Transcription Factor
  •  go-up   go-down


42. Wang Y, Yang J, Gao Y, Zhao XL, Li HZ, Yao Z: [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jul;44(7):522-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between raf kinase inhibitor protein and metastasis of ovarian carcinoma].
  • OBJECTIVE: To investigate the relationship between raf kinase inhibitor protein (RKIP), a novel metastasis suppressor gene, and metastasis of ovarian carcinoma.
  • METHODS: Immunohistochemistry, RT-PCR, and western blot analysis were performed to examine the expression of RKIP in clinical samples of ovarian tumors and five human ovarian carcinoma cell lines.
  • Stable cell lines over-expressed or deleted of RKIP were cloned to investigate the function of RKIP in ovarian cancer cells.
  • The recombinant plasmids expressing sense (ss) or antisense (as) RKIP cDNA or empty vector was transfected into ovarian cancer cell line SKOV3 by lipofectamine.
  • The expression level of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) and extracellular signal-regulated kinase (ERK) in ovarian cancer cells were detected by western blot analysis.
  • (1) The expression levels of RKIP protein in ovarian carcinoma tissues from patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells. patients were found to be reduced than those in ovarian benign tumor and borderline tumor.
  • SKOV3 clones stably expressing full-length recombinant ssRKIP, asRKIP, and their respective empty vector were obtained. (2) RKIP was able to block basal levels of MEK and ERK in ovarian cancer cells.
  • CONCLUSION: RKIP could inhibits the metastasis, but also the growth of ovarian cancer cells.
  • [MeSH-major] Extracellular Signal-Regulated MAP Kinases / metabolism. Mitogen-Activated Protein Kinase Kinases / metabolism. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Phosphatidylethanolamine Binding Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Line, Tumor. Cell Proliferation. Female. Genes, Tumor Suppressor. Genetic Vectors. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Phosphorylation. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transfection. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19957553.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Phosphatidylethanolamine Binding Protein; 0 / RNA, Messenger; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


43. Thomas CM, Boss EA, Boonstra H, van Tienoven D, Sweep CG, Massuger LF: Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors. Eur J Gynaecol Oncol; 2008;29(5):468-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotropins and female sex steroid hormones in cyst fluid and serum from patients with ovarian tumors.
  • The objective of the present study was to determine the concentrations of LH, FSH, 17beta-estradiol and progesterone in ovarian cyst fluid and serum from patients with benign and malignant ovarian tumors and to assess the correlation of the gonadotropin and female sex steroid hormone concentrations with menopausal and tumor status.
  • Ovarian cyst fluid and blood samples were prospectively collected from 103 patients with ovarian tumors.
  • Seventy-four of the patients had benign ovarian tumors while 29 patients had malignant ovarian tumors.
  • Malignant ovarian tumors showed significantly higher LH and FSH cyst fluid concentrations compared to concentrations from patients with benign tumors.
  • Furthermore, LH and FSH cyst fluid concentrations showed strong correlations (r > 0.62) with serum concentrations in case of malignant tumors, especially in postmenopausal women, but not in case of benign tumors.
  • The highest gonadotropin concentrations were observed in cyst fluid from malignant ovarian tumors.
  • Supportive evidence for such an increased vascular permeability is our previous finding of significantly higher VEGF concentrations in cyst fluid from malignant ovarian tumors.
  • The possibility of ectopic production of LH and FSH by malignant ovarian tissue cannot completely be ruled out.
  • [MeSH-major] Cyst Fluid / chemistry. Gonadal Steroid Hormones / analysis. Gonadotropins / analysis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051814.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Gonadotropins; 4G7DS2Q64Y / Progesterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


44. Han XY, Chen Y, Hou MM, Zhang J, Yang KX, Chen YY, Qie MR: [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Jul;39(4):619-22, 634
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of AIB1 protein in epithelial ovarian cancer cells and its impact on apoptosis].
  • OBJECTIVE: To investigate the expression of AIB1 (amplified in breast cancer 1) protein in epithelial ovarian cancer cells and to analyze the relationship between AIB1 protein and the apoptosis modulated proteins: P53 and Bcl-2.
  • METHODS: The expressions of AIB1, P53 and Bcl-2 proteins in 24 normal ovaries, 24 benign ovarian tumors, 18 borderline ovarian tumors and 69 epithelial ovarian cancers were examined with immunohistochemical method SP.
  • 1) The AIB1 protein expressed in 65.22% ovarian cancers, greater than in normal ovaries (8.33%), benign ovarian tumors (25.00%) and borderline ovarian tumors (38.89%).
  • The overexpression of AIB1 protein occurred in 36.23% ovarian cancers.
  • Ovarian cancers poorly-differentiated, at a late clinical stage and with lymph node involvement had higher AIB1 overexpression than those well-differentiated and moderately-differentiated, and those at an early clinical stage and without lymph node involvement.
  • 2) The expression of AIB1 was positively correlated with the expression of P53 (r = 0.342, P = 0.004) and Bcl-2 proteins (r = 0.311, P = 0.009) in the ovarian cancers.
  • CONCLUSION: AIB1 protein expression increases in ovarian cancers, which is associated with the higher malignant biological behavior.
  • The overexpression of AIB1 may be involved in the carcinogenesis and the development of epithelial ovarian cancers through a hormone independent pathway.
  • [MeSH-major] Apoptosis. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Nuclear Receptor Coactivator 3. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / biosynthesis. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18798508.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; EC 2.3.1.48 / Nuclear Receptor Coactivator 3
  •  go-up   go-down


45. Mithieux F, Coriat R, De La Fouchardière C, Méeus P, Rivoire M: [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer]. Gastroenterol Clin Biol; 2008 Mar;32(3):261-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudo-Meigs syndrome: particular management of ovarian metastases in colorectal cancer].
  • [Transliterated title] Le pseudosyndrome de Meigs, particularité dans la prise en charge des métastases ovariennes de cancer colorectal.
  • Ascites and/or pleural effusion with ovarian metastases in colorectal cancer are usually related to peritoneal carcinomatosis.
  • Pseudo-Meigs syndrome is a characterized by non-malignant ascites and/or pleural effusion caused by pelvic tumors other than solid benign ovarian tumors.
  • After ovarian metastasis resection, ascites and pleural diffusion disappeared.
  • In the presence of acellular ascites with ovarian metastases from colorectal cancer, diagnosis of pseudo-Meigs syndrome may allow surgical treatment with curative intent.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Meigs Syndrome / therapy. Ovarian Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18353585.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Zhang J, Ye F, Chen HZ, Ye DF, Lu WG, Xie X: [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr;28(2):173-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma].
  • OBJECTIVE: To investigate the expression of OPCML gene in ovarian epithelial carcinoma and determine the relationship between mRNA expression and methylation of their promoters.
  • METHOD: Twenty normal ovarian tissues and 89 ovarian epithelial tumor specimens (72 malignant, 17 benign), as well as 3 ovarian carcinoma cell lines (SKOV-3, CAOV3, and 3AO), were collected for detection of OPCML gene expression by reverse transcription-polymerase chain reaction and for detection of promoter methylation by restriction enzyme cut analysis from 7.
  • RESULTS: Among ovarian epithelial carcinoma 19.4% expressed OPCML mRNA, while 85% of normal ovarian tissue and 76.5% of benign ovarian tumor.
  • The ratio of expression of OPCML mRNA in ovarian epithelial carcinoma was significantly lower than those of normal (chi2 = 30.108, P = 0.0000) and benign tumors (chi2 = 21.162, P = 0.000).
  • Methylations were detected in 44.4% of cancer cells promoter, while 0% in normal ovarian tissue and benign ovarian tumors.
  • The ratio of methylation of ovarian epithelial carcinoma was significantly higher than those of normal (chi2 = 13.630, P = 0.0000) and benign tumors (chi2 = 11.797, P = 0.000).
  • CONCLUSION: Deletion of OPCML gene exists in ovarian epithelial carcinoma cell.
  • [MeSH-major] Cell Adhesion Molecules / genetics. CpG Islands / genetics. DNA Methylation. Gene Deletion. Ovarian Neoplasms / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. GPI-Linked Proteins. Humans. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733898.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / OPCML protein, human; 0 / RNA, Messenger
  •  go-up   go-down


47. Knüsel PR, Kubik-Huch RA, Komminoth R, Siragusa A, Otto RCh: [Ovarian fibrothecoma: MR imaging findings and differential diagnosis]. Praxis (Bern 1994); 2006 Feb 22;95(8):283-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian fibrothecoma: MR imaging findings and differential diagnosis].
  • [Transliterated title] Fibrothekom des Ovars: MR-bildgebung und Differentialdiagnose.
  • We report the preoperative MR imaging of a 70 year old woman with a large tumor of the lower abdomen.
  • The origin of this tumor was suspected to be either the left ovary or the uterus.
  • In the differential diagnosis a large subserous pedunculated leiomyoma or a low cellular, primarily benign ovarian tumor were considered.
  • [MeSH-major] Fibroma / diagnosis. Magnetic Resonance Imaging. Ovarian Neoplasms / diagnosis. Thecoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hysterectomy. Leiomyoma / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovariectomy. Ovary / pathology. Uterine Neoplasms / diagnosis. Uterus / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523993.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


48. Waalkes MP, Liu J, Ward JM, Powell DA, Diwan BA: Urogenital carcinogenesis in female CD1 mice induced by in utero arsenic exposure is exacerbated by postnatal diethylstilbestrol treatment. Cancer Res; 2006 Feb 1;66(3):1337-45
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Arsenic alone induced some urogenital system tumors, including mostly benign tumors of the ovary and uterus, and adrenal adenoma.
  • Diethylstilbestrol alone induced some tumors (primarily cervical) but when given after in utero arsenic, it greatly enhanced urogenital tumor incidence, multiplicity, and progression.
  • For instance, compared with the incidence of urogenital malignancies in the control (0%), arsenic alone (9%), and diethylstilbestrol alone (21%) groups, arsenic plus diethylstilbestrol acted synergistically, inducing a 48% incidence of malignant urogenital tumors.
  • Of the urogenital tumors induced by arsenic plus diethylstilbestrol, 80% were malignant, and 55% were multiple site.
  • Arsenic plus diethylstilbestrol increased ovarian, uterine, and vaginal tumors, and urinary bladder proliferative lesions, including three transitional cell carcinomas.
  • Tamoxifen alone did not increase urogenital tumors or affect arsenic-induced neoplasia but did increase arsenic-induced uroepithelial proliferative lesions.
  • [MeSH-major] Arsenic / toxicity. Diethylstilbestrol / toxicity. Genital Neoplasms, Female / chemically induced. Kidney Neoplasms / chemically induced. Prenatal Exposure Delayed Effects. Urinary Bladder Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DIETHYLSTILBESTROL .
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452187.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO 12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 094ZI81Y45 / Tamoxifen; 731DCA35BT / Diethylstilbestrol; N712M78A8G / Arsenic
  •  go-up   go-down


49. Medeiros LR, Rosa DD, Edelweiss MI, Stein AT, Bozzetti MC, Zelmanowicz A, Pohlmann PR, Meurer L, Carballo MT: Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):192-202
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review.
  • A quantitative systematic review was performed to estimate the diagnostic accuracy of frozen sections in ovarian tumors.
  • Studies that compared frozen sections and paraffin sections within subjects for diagnosis of ovarian tumors were included.
  • For benign ovarian vs borderline/malignant tumor cases, the occurrence of a positive frozen-section result for benignity (pooled likelihood ratio [LR], 8.7; 95% confidence interval [CI], 7.3-10.4) and posttest probability for benign diagnosis was 95% (95% CI, 94-96%).
  • A positive frozen-section result for malignant vs benign diagnosis (pooled LR, 303; 95% CI, 101-605) increased the probability of ovarian cancer to 98% (95% CI, 97-99%).
  • In borderline vs benign ovarian tumor cases, a positive frozen-section result (pooled LR, 69; 95% CI, 45-106) increased the probability of borderline tumors to 79% (95% CI, 71-85%).
  • In borderline vs malignant ovarian tumor cases, a positive frozen-section result (pooled LR, 18; 95% CI, 13-26) increased the probability of borderline tumors to 51% (95% CI, 42-60%).
  • We conclude that diagnostic accuracy rates for frozen-section analysis is high for malignant and benign ovarian tumors, but the accuracy rates in borderline tumors remain relatively low.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Quality Assurance, Health Care
  • [MeSH-minor] Cryopreservation. Diagnosis, Differential. Female. Humans. Observer Variation. Sensitivity and Specificity. Specimen Handling

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823099.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


50. Tsikouras P, Liberis V, Galazios G, Panagiotidou C, Savidis A, Chatzimachail A, Maroulis G: A 15-year report of pathological and benign ovarian tumors in teenagers. Eur J Gynaecol Oncol; 2008;29(6):602-7
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A 15-year report of pathological and benign ovarian tumors in teenagers.
  • The purpose of this retrospective study was to determine the frequency, clinical aspects and surgical management of ovarian masses in 52 adolescent patients, in whom surgery was deemed necessary, from 1991-2006.
  • We considered age, symptoms, ultrasound investigations, CA 125 levels, family history, operative treatment, surgical complications tumor size, histopathological examinations, pregnancy rate and follow-up.
  • Ovarian lesions in teenagers include a broad array of pathologic diagnoses that have variable and non-specific presenting symptoms.
  • Forty-seven patients (90.4%) had benign lesions, two (3.8%) had borderline tumors and three patients had malignant lesions (5.8%).
  • For benign ovarian disorders the operation should be designed to optimize future fertility while in patients with malignancy, complete staging and resection of the lesion should be the first concern.
  • [MeSH-major] Fertility. Ovarian Cysts / surgery. Ovarian Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115687.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


51. Saba L, Guerriero S, Sulcis R, Virgilio B, Melis G, Mallarini G: Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol; 2009 Dec;72(3):454-63
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mature and immature ovarian teratomas: CT, US and MR imaging characteristics.
  • Ovarian teratomas (OTs) are the most common germ cell neoplasm.
  • They include mature cystic teratomas, monodermal teratomas (neural tumors, struma ovarii, carcinoid tumors) and immature teratomas.
  • Teratomas are the most common benign ovarian neoplasms in women less than 45 years old.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis. Tomography, X-Ray Computed / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804932.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


52. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell JR Jr: Predicting risk of malignancy in adnexal masses. Obstet Gynecol; 2010 Apr;115(4):687-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor morphology derived from ultrasonographic images, tumor size, tumor bilaterality, serum CA 125, and patient demographics were evaluated preoperatively in 395 patients undergoing surgery from 2001 to 2008.
  • Tumor morphology was classified as complex, solid, or cystic.
  • Preoperative findings were compared with tumor histologic findings at the time of surgery.
  • Multivariable classification and regression tree analysis were used to identify a group of patients at high risk of ovarian malignancy.
  • RESULTS: One hundred eighteen patients had ovarian cancer, 13 patients had ovarian tumors of borderline malignancy, and 264 had benign ovarian tumors.
  • Multivariable classification and regression tree analysis defined women at high risk of ovarian malignancy as those with an adnexal mass having complex or solid morphology and a serum CA 125 value greater than 35 units/mL.
  • This definition had a positive predictive value of 84.7% and a negative predictive value of 92.4% and correctly identified 77.3% of patients with stage I and stage II ovarian cancer and 98.6% of patients with stage III and stage IV ovarian cancer.
  • CONCLUSION: Patients with solid or complex ovarian tumors and an elevated serum CA 125 level (greater than 35 units/mL) are at high risk of ovarian malignancy.
  • [MeSH-major] Adnexal Diseases / ultrasonography. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Female. Humans. Middle Aged. Postmenopause. Premenopause. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2010 Apr;115(4):680-1 [20308824.001]
  • (PMID = 20308826.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


53. Hein S, Mahner S, Kanowski C, Löning T, Jänicke F, Milde-Langosch K: Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines. Oncol Rep; 2009 Jul;22(1):177-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Jun and Fos proteins in ovarian tumors of different malignant potential and in ovarian cancer cell lines.
  • They play a role in cell proliferation, malignant transformation and invasion in various tumors.
  • The aim of the current study was to characterize the role of AP-1 in ovarian cancer.
  • Fifty-six ovarian tumors of different invasive potential including 13 metastases as well as 5 ovarian cancer cell lines were analyzed by Western blot analysis regarding their expression of pc-Jun, Jun B, Jun D, c-Fos, Fos B, Fra-1 and Fra-2.
  • The expression of pc-Jun, Jun B, Jun D and Fra-2 was higher in invasive cancer compared to benign tumors.
  • In metastases, c-Fos and Fos B expression was significantly lower than in the respective primary ovarian carcinomas.
  • These results suggest that AP-1 proteins are differentially expressed in benign ovarian tumors, tumors with low malignant potential and epithelial ovarian carcinomas and metastases.
  • No correlation with the proliferative and invasive potential of ovarian cancer cell lines could be found.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Proto-Oncogene Proteins c-jun / metabolism. Transcription Factor AP-1 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Fos-Related Antigen-2 / metabolism. Humans. Middle Aged. Neoplasm Invasiveness. Time Factors


54. Chang YW, Hong SS, Jeen YM, Kim MK, Suh ES: Bilateral sclerosing stromal tumor of the ovary in a premenarchal girl. Pediatr Radiol; 2009 Jul;39(7):731-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovary in a premenarchal girl.
  • Sclerosing stromal tumor (SST) is a rare benign ovarian neoplasm classified as a type of sex cord stromal tumor that occurs predominantly in young patients.
  • We present a case of a bilateral SST of the ovary with calcification in a 12-year-old premenarchal girl and describe the US, CT, MR and pathological findings.
  • [MeSH-major] Diagnostic Imaging / methods. Endometrial Stromal Tumors / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Child. Female. Humans. Menarche. Sclerosis / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23(4):555-7 [10433285.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):194-9 [14530650.001]
  • [Cites] Eur Radiol. 1999;9(7):1335-8 [10460370.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):201-6 [11242213.001]
  • [Cites] Gynecol Oncol. 2006 May;101(2):342-5 [16403568.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Abdom Imaging. 2002 Sep-Oct;27(5):588-91 [12173003.001]
  • [Cites] Pediatr Radiol. 2003 Jan;33(1):56-8 [12497242.001]
  • (PMID = 19283376.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Agaba EI, Ekwempu CC, Ugoya SO, Echejoh GO: Meigs' syndrome presenting as haemorrhagic pleural effusion. West Afr J Med; 2007 Jul-Sep;26(3):253-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The association of a benign ovarian tumor with ascites and hydrothorax that resolve after tumor resection, known as Meigs syndrome is a rare clinical entity.
  • Rarer still is the haemorrhagic form of the syndrome OBJECTIVE: To describe a case of benign ovarian tumour associated with ascites and bloody pleural effusion.
  • RESULTS: The physical examination and a pelvic ultrasonographic scan revealed ascites in addition to a right sided ovarian mass.
  • The pleural effusion and ascites resolved spontaneously thus confirming the diagnosis of Meigs' syndrome.
  • CONCLUSION: Meigs' syndrome should be considered in the differential diagnosis in female patients with hemorrhagic pleural effusion.
  • [MeSH-major] Hemothorax / diagnosis. Meigs Syndrome / diagnosis. Pleural Effusion / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Fibroma / diagnosis. Fibroma / surgery. Hemorrhage / diagnosis. Hemorrhage / etiology. Hemorrhage / surgery. Humans. Ovarian Neoplasms / ultrasonography. Ovariectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399347.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


56. Ødegaard E, Davidson B, Elgaaen BV, Fagerhol MK, Engh V, Onsrud M, Staff AC: Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary. Am J Obstet Gynecol; 2008 Apr;198(4):418.e1-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
  • We investigated whether this is the case for ovarian neoplasms.
  • STUDY DESIGN: Calprotectin was analyzed with an enzyme-linked immunosorbent assay in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n = 89), borderline ovarian tumors (BOT, n = 39), and benign ovarian tumors (n = 71).
  • RESULTS: Median plasma calprotectin concentration was elevated in ovarian carcinoma, compared with controls, as well as compared with BOT (both P < .001).
  • A positive correlation was found between CA 125 and calprotectin concentrations in ovarian carcinoma.
  • CONCLUSION: Plasma calprotectin is elevated in invasive ovarian cancer, but when used as a tumor marker, it is inferior to CA 125.
  • [MeSH-major] Biomarkers, Tumor / blood. Leukocyte L1 Antigen Complex / blood. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241816.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


57. Tsikouras T, Liberis V, Galazios G, Sarri S, Teichmann AT: Contribution of laparoscopy in young women with abdominal pain. Clin Exp Obstet Gynecol; 2007;34(3):168-70
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these, 55 had functional ovarian cysts, eight patients were operated on for adnexal torsion and nine patients had other adnexal conditions.
  • Ovarian cyst resection was performed in 46 patients and ovarian cyst coagulation in 17 patients.
  • In the rest of the 48 patients (40%), 31 (26.67%) cases had pelvic inflammatory disease, three (2.5%) benign ovarian tumors, two (1.6%) ectopic pregnancies, one (0.8%) a paraovarian cyst and 11 (5%) endometriosis.
  • [MeSH-minor] Adolescent. Adult. Endometriosis / diagnosis. Endometriosis / surgery. Female. Humans. Ovarian Cysts / diagnosis. Ovarian Cysts / surgery. Pelvic Inflammatory Disease / diagnosis. Pelvic Inflammatory Disease / surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17937093.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Timmerman D, Van Calster B, Jurkovic D, Valentin L, Testa AC, Bernard JP, Van Holsbeke C, Van Huffel S, Vergote I, Bourne T: Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. J Clin Oncol; 2007 Sep 20;25(27):4194-200
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inclusion of CA-125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors.
  • PURPOSE: To test the value of serum CA-125 measurements alone or as part of a multimodal strategy to distinguish between malignant and benign ovarian tumors before surgery based on a large prospective multicenter study (International Ovarian Tumor Analysis).
  • PATIENTS AND METHODS: Patients with at least one persistent ovarian mass preoperatively underwent transvaginal ultrasonography using gray scale imaging to assess tumor morphology and color Doppler imaging to obtain indices of blood flow.
  • RESULTS: Data from 809 patients recruited from nine centers were included in the analysis; 567 patients (70%) had benign tumors and 242 (30%) had malignant tumors-of these 152 were primary invasive (62.8%), 52 were borderline malignant (21.5%), and 38 were metastatic (15.7%).
  • Results were very similar when the models were prospectively tested on a group of 345 new patients with adnexal masses of whom 126 had malignant tumors (37%).
  • CONCLUSION: Adding information on CA-125 to clinical information and ultrasound information does not improve discrimination of mathematical models between benign and malignant adnexal masses.
  • [MeSH-major] Adnexal Diseases / blood. Adnexal Diseases / diagnosis. Antigens, Neoplasm / blood. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / blood. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2008 Jan 20;26(3):512; author reply 513 [18202431.001]
  • [CommentIn] J Clin Oncol. 2007 Sep 20;25(27):4159-61 [17698803.001]
  • (PMID = 17698805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CA-125 Antigen
  •  go-up   go-down


59. McIntosh MW, Liu Y, Drescher C, Urban N, Diamandis EP: Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma. Clin Cancer Res; 2007 Aug 1;13(15 Pt 1):4422-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
  • PURPOSE: The serum tumor marker CA 125 is elevated in most clinically advanced ovarian carcinomas, and currently, one of the most promising early detection strategies for ovarian cancer uses CA 125 level in conjunction with imaging.
  • However, CA 125 is elevated in only 50% of early-stage ovarian cancer and is often elevated in women with benign ovarian tumors and other gynecologic diseases.
  • The human kallikrein 11 (hK11) marker has been reported to have favorable predictive value for ovarian cancer, although, by itself, it may be inferior to CA 125.
  • CA 125, hK11, and the composite marker were evaluated for their performance in identifying ovarian cancer and for temporal stability.
  • RESULTS: hK11 significantly distinguished ovarian cancer cases from healthy controls and is less sensitive to benign ovarian disease than is CA 125.
  • CONCLUSION: We conclude that hK11 is a valuable new biomarker for ovarian cancer and its temporal stability implies that it may do even better when used in a longitudinal screening program for early detection.
  • [MeSH-major] Biomarkers, Tumor / blood. Ovarian Neoplasms / blood. Serine Endopeptidases / blood
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma, Mucinous / blood. Adenocarcinoma, Mucinous / diagnosis. CA-125 Antigen / metabolism. Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / diagnosis. Case-Control Studies. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / diagnosis. Disease Progression. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Staging. Prognosis. Survival Rate. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17671125.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / R21CA093568
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / trypsin-like serine protease; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


60. Zhao SJ, Liu JY, Ren FR, Feng YJ: [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm]. Zhonghua Fu Chan Ke Za Zhi; 2005 Apr;40(4):264-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of glucose transporter-1 and its correlation with basic fibroblast growth factor and proliferating cell nuclear antigen in epithelial ovarian neoplasm].
  • OBJECTIVE: To study the expression of glucose transporter-1 (GLUT1) and its correlation with basic fibroblast growth factor (bFGF) and proliferating cell nuclear antigen (PCNA) in epithelial ovarian neoplasm.
  • METHODS: Streptavidin-peroxidase complex technique was used to examine the expression of GLUT1, bFGF and PCNA protein in six cases of normal ovarian tissue, 20 cases of benign epithelial tumors, seven cases of borderline tumor and 44 cases of epithelial ovarian carcinoma.
  • RESULTS: In normal ovary and benign ovarian tumor, GLUT1 was not detected, but in borderline ovarian tumor and cancer, the positive expression ratio of GLUT1 was 6/7 and 91% (40/44), respectively.
  • The intensity of GLUT1 in ovarian epithelial neoplasm was significantly higher than in borderline tumors.
  • The staining intensity of GLUT1 was significantly correlated with the histological grade of the tumor (r(S) = 0.499, P = 0.001), and was positively correlated with the clinical stage, cancer invasion and lymph node metastasis.
  • bFGF positive rate in tumor was 57% (25/44).
  • CONCLUSIONS:. (1) The expression of GLUT1 may be closely related to malignant transformation of ovarian epithelial tumors.
  • Both of them play important roles in the carcinogenesis and progression of ovarian epithelial carcinoma.
  • [MeSH-major] Epithelium / metabolism. Fibroblast Growth Factor 2 / metabolism. Glucose Transporter Type 1 / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / metabolism. Proliferating Cell Nuclear Antigen / metabolism
  • [MeSH-minor] Female. Gene Expression Regulation, Neoplastic. Humans. Ovary / metabolism. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15924676.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glucose Transporter Type 1; 0 / Proliferating Cell Nuclear Antigen; 0 / SLC2A1 protein, human; 103107-01-3 / Fibroblast Growth Factor 2
  •  go-up   go-down


61. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J: Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett; 2010;31(3):375-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
  • OBJECTIVE: To analyze the profiles of interleukin-2 (IL-2), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status.
  • We also estimated serum cytokines as biomarkers to distinguish preoperatively between malignant or benign character of tumors.
  • POPULATION: 51 women with epithelial ovarian cancer, 26 with benign ovarian tumors of epithelial origin and 21 healthy controls.
  • RESULTS: We did not found differences in the levels of IFN-gamma, TNF-alpha and IL-2 in all fluids isolated from patients with malignant or benign tumors.
  • Women with advanced cancer had significantly higher serum IL-6, IL-10 and TGF-beta1 levels than women with early stages or benign tumors.
  • The concentrations of IL-6 and IL-8 were higher in ascites of cancer patients than in ascites of women with benign tumors.
  • CONCLUSIONS: Our results indicate on intensified inflammatory process in women with ovarian cancer (accompanied by their immunosuppression).
  • Preoperative analysis of serum IL-6, IL-10 and IL-8 may improve the differential diagnosis of ovarian tumors.
  • [MeSH-major] Ascites / metabolism. Cyst Fluid / metabolism. Cytokines / metabolism. Ovarian Neoplasms / immunology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588232.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


62. Chen M, Wang WC, Zhou C, Zhou NN, Cai K, Yang ZH, Zhao WF, Li SY, Li GZ: Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging. Chin Med Sci J; 2006 Dec;21(4):270-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation between malignant and benign ovarian tumors by magnetic resonance imaging.
  • OBJECTIVE: To determine the magnetic resonance (MR) imaging findings of an ovarian mass which are most predictive of malignancy and assess the value of intravenous gadolinium administration in the characterization of an ovarian mass.
  • Total 70 ovarian masses were detected by contrast-enhanced MR imaging including 37 malignant ovarian masses and 33 benign ovarian masses with 87% (61/70) accuracy, 86% (32/37) sensitivity, 88% (29/33) specificity, 89% (32/36) positive predictive value, and 85% (29/34) negative predictive value, whereas 70 ovarian masses were detected by unenhanced MR imaging with 74% (52/70) accuracy, 73% (27/37) sensitivity, 76% (25/33) specificity, 77% (27/35) positive predictive value, and 71% (25/35) negative predictive value.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249204.001).
  • [ISSN] 1001-9294
  • [Journal-full-title] Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
  • [ISO-abbreviation] Chin. Med. Sci. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


63. Ye S, Hao X, Zhou T, Wu M, Wei J, Wang Y, Zhou L, Jiang X, Ji L, Chen Y, You L, Zhang Y, Xu G, Zhou J, Ma D, Wang S: Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion. BMC Cancer; 2010;10:611
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.
  • However, whether or not Plexin-B1 expression is involved in human ovarian tumors remains unclear.
  • In the present study, Plexin-B1 expression was explored in benign and malignant human ovarian tumor tissues.
  • In addition, the impact of Plexin-B1 expression on ovarian cancer cell proliferation, migration and invasion were investigated in vitro.
  • METHODS: Plexin-B1 expression was analyzed in normal and benign ovarian tissues and serous ovarian tumors (both borderline and malignant) by immunohistochemical staining, as well as in four human ovarian cancer cell lines (A2780, C13*, SKOV3, and OV2008) by RT-PCR and western blot analyses.
  • RESULTS: Expression levels of Plexin-B1 protein were significantly higher in serous ovarian carcinomas than in normal ovaries or benign ovarian neoplasms, and in the former, Plexin-B1 expression was positively correlated with lymphatic metastasis, and the membrane and cytoplasm of cancer cells stained positively.
  • SKOV3 cells displayed the highest Plexin-B1 expression at both the mRNA and protein levels among the four tested human ovarian cancer cell lines and was selected as a cell model for further in vitro experiments.
  • CONCLUSION: Plexin-B1 expression correlates with malignant phenotypes of serous ovarian tumors, probably via phosphorylation of AKT at Ser473, suggesting that Plexin-B1 might be a useful biomarker and/or a novel therapeutic target.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Gene Silencing. Nerve Tissue Proteins / genetics. Ovarian Neoplasms / genetics. Receptors, Cell Surface / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Cell Movement. Cell Proliferation. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Proto-Oncogene Proteins c-akt / metabolism

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12457-62 [11035813.001]
  • [Cites] Mol Cancer. 2009;8:26 [19386116.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3498-504 [11369643.001]
  • [Cites] Trends Immunol. 2001 Dec;22(12):670-6 [11738997.001]
  • [Cites] Sci STKE. 2002 Apr 16;2002(128):re4 [11972358.001]
  • [Cites] Nat Cell Biol. 2002 Sep;4(9):720-4 [12198496.001]
  • [Cites] Ann Hematol. 2002;81 Suppl 2:S74 [12611086.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1885-91 [14559914.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):107-16 [15239958.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2570-82 [15243131.001]
  • [Cites] Neuron. 1995 Jun;14(6):1189-99 [7605632.001]
  • [Cites] Nature. 1996 Oct 10;383(6600):525-8 [8849723.001]
  • [Cites] Cell Oncol. 2009;31(6):423-36 [19940359.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11780-5 [8876214.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1238-44 [9515811.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1235-44 [10087266.001]
  • [Cites] Curr Opin Immunol. 1999 Aug;11(4):387-91 [10448143.001]
  • [Cites] Cell. 1999 Oct 1;99(1):71-80 [10520995.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4321-9 [15632204.001]
  • [Cites] Cell Mol Life Sci. 2005 Jun;62(12):1363-71 [15818466.001]
  • [Cites] Cytokine Growth Factor Rev. 2005 Aug-Oct;16(4-5):535-48 [15979925.001]
  • [Cites] Mol Cell Biol. 2005 Aug;25(16):6889-98 [16055703.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1378-83 [10717620.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):35-45 [11025205.001]
  • [Cites] Biochem J. 2005 Aug 15;390(Pt 1):125-36 [15839837.001]
  • [Cites] Dev Dyn. 2005 Oct;234(2):393-403 [16145665.001]
  • [Cites] Fertil Steril. 2005 Oct;84 Suppl 2:1210-9 [16210013.001]
  • [Cites] Biochem J. 2006 Mar 1;394(Pt 2):459-64 [16187944.001]
  • [Cites] Endothelium. 2006 Mar-Apr;13(2):81-91 [16728327.001]
  • [Cites] Nat Cell Biol. 2006 Jun;8(6):615-22 [16715077.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9017-22 [16754882.001]
  • [Cites] EMBO Rep. 2006 Jul;7(7):704-9 [16799460.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1115-22 [17317819.001]
  • [Cites] OMICS. 2007 Spring;11(1):41-57 [17411395.001]
  • [Cites] Annu Rev Cell Dev Biol. 2007;23:263-92 [17539753.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34888-95 [17855350.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19040-5 [18024597.001]
  • [Cites] J Biol Chem. 2008 Jan 25;283(4):1893-901 [18025083.001]
  • [Cites] Oncology. 2007;72(3-4):172-80 [18097168.001]
  • [Cites] Transl Res. 2008 Mar;151(3):134-40 [18279812.001]
  • [Cites] Protein Sci. 2008 Jun;17(6):1003-14 [18411422.001]
  • [Cites] Am J Pathol. 2008 Aug;173(2):545-60 [18599607.001]
  • [Cites] Mol Biol Cell. 2009 Mar;20(6):1728-36 [19158377.001]
  • [Cites] PLoS One. 2009;4(4):e5052 [19337377.001]
  • [Cites] Curr Biol. 2001 Mar 6;11(5):339-44 [11267870.001]
  • (PMID = 21059203.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / PLXNB1 protein, human; 0 / Receptors, Cell Surface; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2991310
  •  go-up   go-down


64. Lutgendorf SK, Lamkin DM, DeGeest K, Anderson B, Dao M, McGinn S, Zimmerman B, Maiseri H, Sood AK, Lubaroff DM: Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun; 2008 Aug;22(6):890-900
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients.
  • The adaptive immune response of ovarian cancer patients has been linked to survival, and is known to be impaired in the tumor microenvironment.
  • Little is known about relationships between biobehavioral factors such as depressed mood and anxiety and the adaptive immune response in ovarian cancer.
  • Thirty-seven patients with epithelial ovarian cancer and 14 patients with benign ovarian neoplasms completed psychosocial questionnaires pre-surgery.
  • Lymphocytes from peripheral blood, tumor, and ascites (fluid around the tumor), were obtained on the day of surgery.
  • Expression of the Type-1 cytokine interferon-gamma (IFN gamma), and the Type-2 cytokine interleukin-4 (IL-4) by T-helper (CD4(+)) and T-cytotoxic (CD8(+)) cells was measured under autologous tumor-stimulated, polyclonally-stimulated, or unstimulated conditions.
  • Among cancer patients, marked elevations in unstimulated and tumor-stimulated Type-2 responses were seen, particularly in ascites and tumor-infiltrating lymphocytes (P values<0.01).
  • Although effects of polyclonal stimulation should be generalized with caution to the in vivo immune response, findings suggest that depressed and anxious mood are associated with greater impairment of adaptive immunity in peripheral blood and in the tumor microenvironment among ovarian cancer patients.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1995 Nov;1(11):1327-35 [9815928.001]
  • [Cites] Psychol Rev. 1998 Jan;105(1):83-107 [9450372.001]
  • [Cites] J Formos Med Assoc. 1999 Jan;98(1):24-30 [10063270.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6671-80 [10352285.001]
  • [Cites] Cancer Immunol Immunother. 1999 May-Jun;48(2-3):147-52 [10414469.001]
  • [Cites] J Immunol. 1999 Aug 15;163(4):1923-8 [10438927.001]
  • [Cites] Adv Exp Med Biol. 1999;461:1-24 [10442164.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2492-9 [10452985.001]
  • [Cites] J Exp Med. 1999 Sep 6;190(5):617-27 [10477547.001]
  • [Cites] J Psychosom Res. 2004 Oct;57(4):353-8 [15518669.001]
  • [Cites] Am J Obstet Gynecol. 2004 Nov;191(5):1598-605 [15547530.001]
  • [Cites] Ann Oncol. 2005 Apr;16(4):590-6 [15699022.001]
  • [Cites] Psychosom Med. 2005 Jul-Aug;67(4):638-42 [16046380.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):571-80 [16397274.001]
  • [Cites] Brain Behav Immun. 2007 Feb;21(2):185-94 [16908118.001]
  • [Cites] Brain Behav Immun. 2007 May;21(4):374-83 [17360153.001]
  • [Cites] Springer Semin Immunopathol. 1999;21(3):231-48 [10666771.001]
  • [Cites] J Consult Clin Psychol. 2000 Feb;68(1):31-45 [10710838.001]
  • [Cites] Ann Behav Med. 2000 Winter;22(1):29-37 [10892526.001]
  • [Cites] Nat Med. 2001 Feb;7(2):206-14 [11175852.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:94-105 [11268424.001]
  • [Cites] Surgery. 2001 Jun;129(6):749-56 [11391375.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Jun;91(6):654-8 [11402277.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2001 Aug;56(8):M477-82 [11487599.001]
  • [Cites] J Immunol. 2001 Dec 1;167(11):6497-502 [11714817.001]
  • [Cites] Brain Behav Immun. 2002 Feb;16(1):1-16 [11846437.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Exp Med. 2003 Feb 3;197(3):387-93 [12566422.001]
  • [Cites] Brain Behav Immun. 2003 Apr;17(2):69-85 [12676570.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6784-90 [14583474.001]
  • [Cites] Int J Gynecol Cancer. 2004 Jan-Feb;14(1):64-75 [14764031.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):1-8 [14987957.001]
  • [Cites] J Immunol. 2004 May 1;172(9):5467-77 [15100288.001]
  • [Cites] Psychol Bull. 2004 Jul;130(4):601-30 [15250815.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1024:138-46 [15265778.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3570-80 [15337807.001]
  • [Cites] Lancet Oncol. 2004 Oct;5(10):617-25 [15465465.001]
  • [Cites] Cancer Res. 1981 Mar;41(3):1133-9 [7193084.001]
  • [Cites] J Pers Assess. 1983 Jun;47(3):305-6 [6886962.001]
  • [Cites] Obstet Gynecol. 1984 Nov;64(5):708-14 [6493663.001]
  • [Cites] Mol Pharmacol. 1987 Apr;31(4):377-84 [3033466.001]
  • [Cites] J Consult Clin Psychol. 1989 Dec;57(6):683-91 [2600238.001]
  • [Cites] J Immunol. 1990 Mar 15;144(6):2211-5 [1968925.001]
  • [Cites] J Immunol. 1991 Mar 1;146(5):1700-7 [1704404.001]
  • [Cites] Immunol Lett. 1991 Sep;30(1):141-2 [1683651.001]
  • [Cites] JAMA. 1992 Mar 4;267(9):1244-52 [1538563.001]
  • [Cites] Gynecol Obstet Invest. 1993;35(2):118-20 [8383627.001]
  • [Cites] Brain Behav Immun. 1993 Jun;7(2):154-63 [8394164.001]
  • [Cites] Lymphokine Cytokine Res. 1993 Dec;12(6):429-37 [8123759.001]
  • [Cites] Proc Assoc Am Physicians. 1996 Sep;108(5):374-81 [8902882.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):276-84 [8903466.001]
  • [Cites] J Allergy Clin Immunol. 1996 Dec;98(6 Pt 2):S161-73 [8977524.001]
  • [Cites] Cell Immunol. 1997 Feb 1;175(2):150-6 [9023420.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):30-6 [9428780.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • (PMID = 18276105.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104825-01; United States / NCI NIH HHS / CA / R21CA88293; United States / NCI NIH HHS / CA / R01CA104825; United States / NCI NIH HHS / CA / R01 CA104825; United States / NCI NIH HHS / CA / R21 CA088293-01; United States / NCI NIH HHS / CA / CA088293-01; United States / NCI NIH HHS / CA / R21 CA088293; United States / NCI NIH HHS / CA / R01 CA104825-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interferon Type I; 207137-56-2 / Interleukin-4
  • [Other-IDs] NLM/ NIHMS59847; NLM/ PMC2605940
  •  go-up   go-down


65. Lambeck A, Leffers N, Hoogeboom BN, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout JW, Platteel I, Offringa R, Hollema H, Melief K, van der Burg S, van der Zee A, Daemen T, Nijman H: P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy. Int J Cancer; 2007 Aug 1;121(3):606-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] P53-specific T cell responses in patients with malignant and benign ovarian tumors: implications for p53 based immunotherapy.
  • Despite intensive treatment, 70% of the ovarian cancer patients will develop recurrent disease, emphasizing the need for new approaches such as immunotherapy.
  • A promising antigenic target for immunotherapy in ovarian cancer is the frequently overexpressed p53 protein.
  • The aim of the study was to evaluate the nature and magnitude of the baseline anti-p53 immune response in ovarian cancer patients.
  • P53-specific T cell responses were detected in both half of the ovarian cancer patients as in the group of control subjects, consisting of women with benign ovarian tumors and healthy controls.
  • Importantly, while in the control group p53-specific immunity was detected among the CD45RA(+) naïve subset of T cells only, the p53-specific T-cell responses in ovarian cancer patients were also present in the CD45RO(+) memory T-cell subset, suggesting that in the cancer patients sufficient amounts of cancer-derived p53 was presented to induce the formation of a p53-specific memory T-cell response.
  • Notably, p53-specific T cells were not only detected in the peripheral blood, but also among tumor infiltrating lymphocytes and in tumor-draining lymph nodes.
  • [MeSH-major] Ovarian Neoplasms / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD45. Cytokines / metabolism. Female. Humans. Immunologic Memory. Interferon-gamma / metabolism. Lymph Nodes / immunology. Lymphocyte Activation. Middle Aged. Protein Tyrosine Phosphatase, Non-Receptor Type 1. Tumor Suppressor Protein p53

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17415711.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Tumor Suppressor Protein p53; 82115-62-6 / Interferon-gamma; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 1
  •  go-up   go-down


66. Kamat AA, Baldwin M, Urbauer D, Dang D, Han LY, Godwin A, Karlan BY, Simpson JL, Gershenson DM, Coleman RL, Bischoff FZ, Sood AK: Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker. Cancer; 2010 Apr 15;116(8):1918-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
  • BACKGROUND: Cell-free DNA reflects both normal and tumor-derived DNA released into the circulation through cellular necrosis and apoptosis.
  • The authors sought to determine the role of preoperative total plasma cell-free DNA levels in predicting clinical outcome in patients with ovarian cancer.
  • METHODS: After institutional review board consent, DNA was extracted from plasma of 164 women with invasive epithelial ovarian carcinoma (EOC), 49 with benign ovarian neoplasms, and 75 age-matched controls.
  • In the training set, EOC patients had a median preoperative cell-free DNA level of 10,113 GE/mL, compared with patients with benign ovarian neoplasms (median, 2365 GE/mL; P < .0001) and controls (median, 1912 GE/mL, P < .0001).
  • Elevated plasma cell-free DNA is an independent predictor for death from disease in ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:161-8 [10818614.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2222-7 [11489795.001]
  • [Cites] Clin Chem. 2001 Sep;47(9):1607-13 [11514393.001]
  • [Cites] Anticancer Res. 2002 Jan-Feb;22(1A):421-5 [12017326.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Cancer Treat Rev. 2002 Oct;28(5):255-71 [12435372.001]
  • [Cites] J Natl Cancer Inst. 2002 Nov 20;94(22):1697-703 [12441325.001]
  • [Cites] Reprod Biomed Online. 2003 Apr-May;6(3):349-51 [12735873.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):288-91 [12872347.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3902-8 [14507943.001]
  • [Cites] Int J Gynecol Cancer. 2004 May-Jun;14(3):459-64 [15228418.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6476-81 [15374957.001]
  • [Cites] Head Neck. 2004 Oct;26(10):878-83 [15390201.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4157-64 [15483026.001]
  • [Cites] J Immunol Methods. 1975 Dec;9(2):157-64 [1206227.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jun;23(6):707-12 [3653190.001]
  • [Cites] Am J Obstet Gynecol. 1988 Aug;159(2):341-6 [2457318.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2968-75 [8918494.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):768-75 [9529358.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1394-9 [15746038.001]
  • [Cites] Cancer Biol Ther. 2006 Oct;5(10):1369-74 [16969071.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • (PMID = 20166213.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD050128; United States / NCI NIH HHS / CA / P50 CA083639-090008; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA083639-090008; United States / NICHD NIH HHS / HD / K12 HD050128
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS189699; NLM/ PMC2854845
  •  go-up   go-down


67. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol; 2010 Aug 1;118(2):189-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer.
  • Overexpression of EVI1 in ovarian cancer has led to a proposed oncogenic role.
  • Our objective was to evaluate the therapeutic potential of EVI1 and EVI1s (also known as Delta324) in ovarian cancer.
  • METHODS: Expression of EVI1 mRNA and protein isoforms was evaluated in ovarian cancers, normal ovaries, benign ovarian neoplasms, and fallopian tube fimbria.
  • RESULTS: EVI1 and EVI1s mRNAs were ubiquitously expressed in ovarian cancers and benign gynecologic tissues examined, with highest expression of both isoforms noted in the cancer samples.
  • In contrast, EVI1 protein isoform levels were undetectable in normal ovarian tissues, and highest in serous ovarian cancers.
  • EVI1 protein expression patterns were similar between serous ovarian cancer samples, fallopian tube fimbria, and benign neoplasms.
  • Total and isoform selective knockdown of EVI1 isoforms in EVI1 expressing ovarian cancer cells had no effect on proliferation, cisplatin-induced apoptosis, or gamma-H2AX levels in ovarian cancer cells.
  • CONCLUSION: Our data do not support a role for EVI1 or EVI1s in ovarian cancer cell proliferation or response to DNA damage.
  • Further research is required before EVI1 can be considered an oncogene or a therapeutic target in ovarian cancer.
  • [MeSH-major] DNA-Binding Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Cell Growth Processes / drug effects. Cell Growth Processes / genetics. Cell Line, Tumor. Cisplatin / pharmacology. DNA Damage. Drug Delivery Systems. Female. Gene Knockdown Techniques. Humans. Middle Aged. Protein Isoforms. Proto-Oncogenes / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20462630.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Transcription Factors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Akçay T, Dinçer Y, Alademir Z, Aydinli K, Arvas M, Demirkiran F, Kösebay D: Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2005 Mar 1;119(1):108-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To demonstrate O6-methylguanine-DNA methyltransferase (MGMT) and glutathione S-transferase (GST) activities by analyzing the sera separately obtained from patients with malignant ovarian tumors, benign ovarian tumors, and healthy individuals.
  • STUDY DESIGN: Fourty-nine patients with ovarian cancer, nine patients with benign tumors, and 22 healthy women were included in this study.
  • Blood samples were obtained from all the subjects in the malignant-tumor, benign-tumor, and control groups.
  • Patients with malignant tumors underwent second and third phlebotomies one week following the surgery and after the chemotherapy regimen, respectively.
  • RESULTS: Our work demonstrated that untreated patients with malignant ovarian tumors revealed significantly greater MGMT and GST activities in their sera than did both healthy individuals and patients with benign ovarian tumors, while no significant difference was found between the healthy group and the patients with benign ovarian tumors with respect to their sera MGMT and GST activities.
  • A relationship between sera MGMT and GST activities, tumor histology and pathology was not found in this study.
  • CONCLUSION: Our work suggests the fact that detection of sera MGMT and GST activities is important in diagnostic and therapeutic approaches during the course of ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Glutathione Transferase / blood. Neoplasms, Glandular and Epithelial / blood. O(6)-Methylguanine-DNA Methyltransferase / blood. Ovarian Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734094.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione Transferase; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


69. Zhong M, Li J, Ding YQ, Song LL: [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Dec;23(6):665-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ZNF217 gene was detected in ovarian serous cystadenocarcinoma by fluorescence in situ hybridization].
  • OBJECTIVE: To investigate amplification of zinc finger protein 217 (ZNF217) gene in ovarian serous cystadenocarcinoma and its clinical significance.
  • METHODS: Twenty three specimens of ovarian carcinoma, 10 specimens of ovarian benign tumors and 7 specimens of normal ovaries and two ovarian cancer cell lines, SKOV3 and HO-8910 were examined by fluorescence in situ hybridization (FISH).
  • RESULTS: The amplification of ZNF217 was gained in 12 case of ovarian cancers, there was only 1 case in ovarian benign tumor and not amplication in normal ovary.
  • CONCLUSION: The amplification of ZNF217 is associated with ovarian cancer.
  • Oncogenes ZNF217 maybe play a role in cell differentiation and indicate poorer survival in patients with ovarian cancer.
  • [MeSH-major] Cystadenocarcinoma, Serous / genetics. Ovarian Neoplasms / genetics. Trans-Activators / genetics
  • [MeSH-minor] Adult. Aged. Cell Differentiation. Cell Line, Tumor. Cystadenoma, Serous / genetics. Cystadenoma, Serous / pathology. Female. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Staging. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160949.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Trans-Activators; 0 / ZNF217 protein, human
  •  go-up   go-down


70. Briones-Landa CH, Ayala-Yáñez R, Leroy-López L, Anaya-Coeto H, Santarosa-Pérez MA, Reyes-Muñoz E: [Comparison of laparoscopic vs. laparotomy treatment in ovarian teratomas]. Ginecol Obstet Mex; 2010 Oct;78(10):527-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of laparoscopic vs. laparotomy treatment in ovarian teratomas].
  • [Transliterated title] Comparación del tratamiento laparoscópico vs laparotomía en teratomas ováricos.
  • BACKGROUND: Benign cystic teratoma is one of the most common benign tumors of the ovary, according to international series represents between 44 and 62% of all ovarian tumors diagnosed in women younger than 40 years.
  • OBJECTIVES: To evaluate and compare the efficacy and safety between laparoscopy and laparotomy in the management of ovarian teratomas, as well as the recurrence between both techniques.
  • MATERIALS AND METHOD: Retrospective, clinical series study involving 169 cases of ovarian teratomas operated at the Instituto Nacional de Perinatología Isidro Espinosa de los Reyes in the period comprehended between 2000-2008.
  • Laparoscopy was a risk factor for broken open for ovarian cyst (OR: 6.9; CI 95%: 3.3-14.8).
  • [MeSH-major] Laparoscopy. Laparotomy. Ovarian Neoplasms / surgery. Teratoma / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Blood Loss, Surgical. CA-125 Antigen / blood. Dermoid Cyst / blood. Dermoid Cyst / surgery. Dermoid Cyst / ultrasonography. Female. Humans. Intraoperative Complications / etiology. Length of Stay / statistics & numerical data. Ovarian Cysts / blood. Ovarian Cysts / surgery. Ovarian Cysts / ultrasonography. Postoperative Complications / epidemiology. Predictive Value of Tests. Retrospective Studies. Rupture / etiology. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21966769.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


71. Turker O, Dogan I, Kumanlioglu K: Radioiodine accumulation in a large adnexal cystadenofibroma. Thyroid; 2010 May;20(5):561-2
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report a patient with marked radioiodine accumulation in a large adnexal cystadenofibroma, a benign ovarian tumor.
  • Pathologic examination revealed a benign cystadenofibroma without any coexisting thyroid tissue.
  • The mechanism for radioiodine accumulation in this patient's tumor is unclear.
  • [MeSH-major] Cystadenoma / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Papillary / radiotherapy. Carcinoma, Papillary / surgery. False Positive Reactions. Female. Goiter, Nodular / surgery. Humans. Hysterectomy. Iodine Radioisotopes / pharmacokinetics. Middle Aged. Ovariectomy. Thyroid Neoplasms / radiotherapy. Thyroid Neoplasms / surgery. Thyroidectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20406107.001).
  • [ISSN] 1557-9077
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


72. Grammatikakis I, Ivanov S, Evangelinakis N, Zevoudis S, Tziortzioti V: [Incidence of synchronous primary neoplasms of the female reproductive tract in women with ovarian endometriosis: a retrospective analysis of 811 cases]. Akush Ginekol (Sofiia); 2009;48(3):26-30
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of synchronous primary neoplasms of the female reproductive tract in women with ovarian endometriosis: a retrospective analysis of 811 cases].
  • PURPOSE: Although endometriosis is a benign disorder recent studies suggest endometriosis could be viewed as a neoplastic process.
  • Objective of this study is to explore the epidemiology of synchronous neoplasms (SPN) in women with severe endometriosis.
  • PATIENTS & METHODS: The prevalence of SPN in cases with endometriotic ovarian cysts that underwent surgery at "Lito" Maternity hospital of Athens and at Anticancer Institute of Sophia was investigated.
  • The medical records and pathology were reviewed to confirm the diagnosis and stage of tumors.
  • Similarly, 4 out of 5 ovarian cancers were endometrioid, while one was serum cystadenosarcoma.
  • All of the ovarian malignancies were grade I (Ib in 3 and Ia in 2).
  • Median diameter of the ovarian neoplasias was 4.3 cm, in contradiction to 4.5 cm that was the median diameter of all endometrioid cysts.
  • When only the larger ovarian malignant cyst in each patient was accounted, then median diameter was calculated as 5.8 cm.
  • CONCLUSIONS: Women with synchronous primary cancers of the endometrium and ovary have distinct clinical characteristics including younger age, premenopausal status, and nulliparity.
  • [MeSH-major] Carcinoma, Endometrioid / epidemiology. Endometriosis / epidemiology. Neoplasms, Multiple Primary / epidemiology. Ovarian Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bulgaria / epidemiology. Female. Greece / epidemiology. Humans. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Uterine Neoplasms / epidemiology. Uterine Neoplasms / pathology. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198760.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


73. Zhang LL, Shao SL, Wu Y: [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance]. Chin J Cancer; 2010 Jan;29(1):25-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of osteopontin and B7-H4 in epithelial ovarian neoplasm and their significance].
  • BACKGROUND AND OBJECTIVE: Epithelial ovarian cancer involves a number of factors.
  • Recent studies have shown that osteopontin (OPN) is related to the occurrence and development of a variety of tumors, but few studies are on ovarian cancer.
  • B7-H4 is a newly identified tumor marker in ovarian cancer.
  • This study explored the expression of OPN and B7-H4 and their clinical significance in epithelial ovarian tumors.
  • METHODS: The expression of OPN and B7-H4 in 15 cases of normal ovarian tissue, 20 of benign ovarian tumor tissue, 20 of borderline ovarian tumor tissue, and 40 of ovarian cancer tissue were detected by immunohistochemistry, and the relationship of OPN and B7-H4 expression to clinical and pathologic features of ovarian cancer was analyzed.
  • RESULTS: The expression of OPN and B7-H4 were significantly higher in ovarian cancer than in borderline and benign tumors (P<0.05).
  • The positive rates of OPN and B7-H4 were significantly higher in poorly differentiated ovarian cancer than in medium and highly differentiated ovarian cancer (P<0.05), and the levels of expression were significantly lower in tissue at stages I and III of ovarian cancer than in stages III and IV (P<0.05).
  • The positive rate of B7-H4 were significantly higher in ovarian serous carcinoma than in the mucinous carcinoma (P<0.05), but did not relate to age and lymph node metastasis.
  • CONCLUSION: The expression of OPN and B7-H4 increased in epithelial ovarian cancer, which could be referenced in the diagnosis of ovarian malignant tumors.
  • [MeSH-major] Cystadenocarcinoma, Serous / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Osteopontin / metabolism. Ovarian Neoplasms / metabolism. V-Set Domain-Containing T-Cell Activation Inhibitor 1 / metabolism
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Ovary / metabolism. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038306.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / SPP1 protein, human; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 106441-73-0 / Osteopontin; Ovarian epithelial cancer
  •  go-up   go-down


74. Tomas D, Lenicek T, Tuckar N, Puljiz Z, Ledinsky M, Kruslin B: Primary ovarian leiomyoma associated with endometriotic cyst presenting with symptoms of acute appendicitis: a case report. Diagn Pathol; 2009;4:25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian leiomyoma associated with endometriotic cyst presenting with symptoms of acute appendicitis: a case report.
  • BACKGROUND: Ovarian leiomyoma is a rare benign tumor that accounts for 0.5 to 1% of all benign ovarian tumors.
  • It probably arises from smooth muscle cells in the ovarian hilar blood vessels but there are other possible origins including cells in the ovarian ligament, smooth muscle cells or multipotential cells in the ovarian stroma, undifferentiated germ cells, or cortical smooth muscle metaplasia.
  • Additionally, smooth muscle metaplasia of endometriotic stroma, smooth muscle present in mature cystic teratomas, and smooth muscle in the walls of mucinous cystic tumor may explain their occurrence in the ovary in some cases.
  • Upon laparotomy, there was a solid, oval left-sided ovarian tumor located behind the uterus.
  • The tumor was sent to the pathology department.
  • A diagnosis of primary ovarian leiomyoma associated with an endometriotic cyst was established.
  • CONCLUSION: The origin of ovarian leiomyoma is still unresolved.
  • In our case, the tumor probably arose from smooth muscle cells derived from myofibroblasts that originate from metaplastic ovarian stromal cells present in the rim of the endometriotic cyst.
  • Despite its rarity, ovarian leiomyoma should be considered in the differential diagnosis of ovarian spindle cell tumors.
  • Appropriate diagnosis may require additional immunohistochemical analysis in some cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2009 Feb;17(1):38-40 [18397899.001]
  • [Cites] Histopathology. 2000 Apr;36(4):348-52 [10759949.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):733-5 [15581993.001]
  • [Cites] Cancer. 1961 Sep-Oct;14:989-1000 [13752348.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):63-8 [9891243.001]
  • [Cites] Int J Gynecol Pathol. 1999 Jan;18(1):58-62 [9891242.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):226-9 [9367713.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 2):872-3 [8677121.001]
  • [Cites] Arch Pathol Lab Med. 1993 Aug;117(8):802-8 [7688213.001]
  • [Cites] Arch Pathol Lab Med. 1992 Oct;116(10):1068-71 [1417447.001]
  • [Cites] Am J Surg Pathol. 1991 Nov;15(11):1055-62 [1656803.001]
  • [Cites] Am J Obstet Gynecol. 1989 Jul;161(1):177-8 [2750800.001]
  • [Cites] Arch Pathol Lab Med. 1981 Oct;105(10):505-7 [6895159.001]
  • [Cites] J Obstet Gynaecol. 1999 Nov;19(6):676 [15512440.001]
  • [Cites] J Obstet Gynaecol. 1997 Sep;17(5):503-4 [15511944.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1436-51 [15489647.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):584-90 [12808064.001]
  • [Cites] Clin Imaging. 2000 Jan-Feb;24(1):34-7 [11120415.001]
  • [Cites] J Pediatr Adolesc Gynecol. 2008 Feb;21(1):33-6 [18312799.001]
  • (PMID = 19642987.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2724421
  •  go-up   go-down


75. Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C: Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol; 2009 May;113(2):221-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
  • OBJECTIVES: To improve the poor survival in ovarian cancer (OC) patients, the research has been focused on new OC markers.
  • These aims were addressed in the present study by evaluating serum tetranectin (TN) and serum CA125 on a large number of pre- and postmenopausal women with ovarian tumors and controls.
  • METHODS: The potential ability of the markers to discriminate between the four groups (208 benign ovarian tumor, 153 borderline ovarian tumor (BOT), 445 OC and 1333 age matched controls) in OC screening was examined.
  • We also constructed a risk assessment index (RAI) for discrimination between tumor groups based on these variables and menopausal status.
  • A very high probability of having OC or a benign tumor, respectively, was predicted by the RAI.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lectins, C-Type / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Diseases / blood. Ovarian Diseases / diagnosis. Ovarian Diseases / pathology. Postmenopause / blood. Premenopause / blood. Preoperative Care. Risk Assessment

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261323.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Lectins, C-Type; 109489-77-2 / tetranectin
  •  go-up   go-down


76. Zhao Q, Duan W, Wu YM, Qian XH, Deng XH: [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):754-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
  • OBJECTIVE: To find new serum tumor markers for ovarian epithelial cancers by 2-DE DIGE and MALDI-TOF/TOF proteomic methods, in order to improve the diagnostic sensitivity and specificity.
  • METHODS: Serum samples from 103 cases of ovarian epithelial cancers, 60 cases of healthy women, 63 cases of benign ovarian tumors and 63 cases of benign pelvic diseases were collected.
  • Sera of 20 cases of ovarian epithelial cancers (A), 20 cases of ovarian benign tumors (B), 20 cases of pelvic benign diseases (C) and 20 cases of health control (D) were matched by age and pooled, respectively.
  • After depletion of high abundance serum albumin and IgG, the samples were assayed by 2-DE DIGE.
  • 2) Western blot and ELISA proved that there were significant differences in Hp and Tf between ovarian epithelial cancers and normal controls (P = 0.000), between ovarian epithelial cancers and ovarian benign tumors (P = 0.000), between ovarian epithelial cancers and benign pelvic disease sera (P = 0.000).
  • 3) CA125 + Hp + Tf combined detection of ovarian cancer had higher sensitivity and specificity than CA125, Hp or Tf detection alone.
  • CONCLUSION: Hp and Tf are differently expressed in the sera of patients with ovarian epitheliual cancers.
  • They can be used as serum biomarkers for ovarian epithelial cancers.
  • CA125 + Hp + Tf combined detection may improve the sensitivity and specificity of diagnosis of ovarian epithelial cancers.
  • [MeSH-major] Cystadenocarcinoma, Serous / blood. Haptoglobins / analysis. Ovarian Neoplasms / blood. Proteins / analysis. Transferrin / analysis
  • [MeSH-minor] Adenocarcinoma, Clear Cell / blood. Biomarkers, Tumor / blood. Cystadenocarcinoma, Mucinous / blood. Electrophoresis, Gel, Two-Dimensional. Endometriosis / blood. Female. Humans. Pelvic Inflammatory Disease / blood. Proteomics. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Teratoma / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173805.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Haptoglobins; 0 / NBR1 protein, human; 0 / Proteins; 0 / Transferrin
  •  go-up   go-down


77. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S, Scambia G: Expression of CD133-1 and CD133-2 in ovarian cancer. Int J Gynecol Cancer; 2008 May-Jun;18(3):506-14
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of CD133-1 and CD133-2 in ovarian cancer.
  • Cancer stem cells have been isolated from several solid tumors including prostate, colon, liver, breast, and ovarian cancer.
  • The aims of this study were to investigate the expression of the CD133-1 and CD133-2 epitopes in primary ovarian tumors and to biologically characterize CD133(+) ovarian cancer cells, also according to clinicopathologic parameters.
  • Tissue specimens were obtained at primary surgery from 41 ovarian carcinomas; eight normal ovaries and five benign ovarian tumors were also collected.
  • The percentages of CD133-1- and CD133-2-expressing cells were significantly lower in normal ovaries/benign tumors with respect to those in ovarian carcinoma.
  • Both the percentages of CD133-1- and CD133-2-expressing cells were significantly lower in omental metastases than in primary ovarian cancer (P = 0.009 and 0.007 for CD133-1- and CD133-2-expressing cells, respectively).
  • CD133-1 and CD133-2 may be useful in order to select and enrich the population of CD133(+) ovarian tumor cells, which are characterized by a higher clonogenic efficiency and proliferative potential.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Neoplasm Invasiveness / pathology. Ovarian Neoplasms / mortality. Ovarian Neoplasms / pathology. Peptides / metabolism
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Flow Cytometry. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Probability. Prognosis. Reference Values. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868344.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AC133 antigen; 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Peptides
  •  go-up   go-down


78. Simon I, Katsaros D, Rigault de la Longrais I, Massobrio M, Scorilas A, Kim NW, Sarno MJ, Wolfert RL, Diamandis EP: B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression. Gynecol Oncol; 2007 Aug;106(2):334-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
  • OBJECTIVE: This study characterizes the expression of the novel biomarker B7-H4 in ovarian cancer tissue, normal ovaries, and benign ovarian tumors, and evaluates its relationship to CA125.
  • METHODS: Ovarian tissue lysates from 251 patients with ovarian carcinoma were assessed for the levels of B7-H4 and CA125 by ELISA assays.
  • For comparison, ovarian tissues from patients with benign ovarian tumors (n=43) and patients with normal ovaries (n=32) were tested.
  • B7-H4 was elevated in tumors of 30 patients with early stage cancer that were negative for CA125.
  • CONCLUSION: B7-H4 expression was low in normal ovaries and in benign tumors while half of early stage and two-thirds of late stage cancers over-expressed B7-H4.
  • The data are consistent with previous observations and support further investigation of B7-H4 in the detection of early stage ovarian cancer either alone, or in combination with CA125.
  • [MeSH-major] Antigens, CD80 / biosynthesis. Biomarkers, Tumor / biosynthesis. CA-125 Antigen / biosynthesis. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. V-Set Domain-Containing T-Cell Activation Inhibitor 1

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498784.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / V-Set Domain-Containing T-Cell Activation Inhibitor 1; 0 / VTCN1 protein, human
  •  go-up   go-down


79. Sorak M, Arsenijević S, Lukić G, Arsenijević N, Ristić P, Pavlović S, Popović S, Baskić D: Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. J BUON; 2007 Jan-Mar;12(1):99-104
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
  • PURPOSE: The aim of this prospective study was to determine serum levels and tissue expression of CA125, CA 15-3, p53, HER-2 and nm23 tumor markers, which are used in the detection and follow up of patients with ovarian carcinoma.
  • PATIENTS AND METHODS: 19 patients with malignant and benign ovarian tumors were included in this study.
  • Serum levels of CA125, CA 15-3 and p53 tumor markers were detected in preoperative and postoperative blood samples using ELISA technique.
  • RESULTS: All serum tumor markers were elevated in patients with ovarian carcinoma.
  • Serum level of CA 15-3 was increased in patients with ovarian carcinoma (median 48.33 U/ml, normal range 0-36), while it was normal in patients with benign ovarian tumors (median 20.67 U/ml; p >0.05).
  • CA125 serum values were strikingly increased in ovarian carcinoma (median 264.16 IU/ml, normal range 0-35) and benign ovarian tumors (median 119.59 IU/ml; p <0.05).
  • Serum levels of p53 in patients with ovarian carcinoma were increased (median 0.69 U/ml, normal range 0-0.50) compared to patients with benign tumors (0.32 U/ml; p <0.05).
  • Histological HER-2 overexpression was detected in 7 cases, including 4 with strong (score 3+ and 2+) and 3 with weak or no HER-2 expression (score 1+ and 0) in ovarian carcinoma tissue; in benign tumors HER-2 overexpression was detected in 1 case (p >0.05).
  • Strong overexpression of p53 was detected in 3 cases with malignant and none with benign tumors (p >0.05); and strong overexpression of nm23 was detected in 5 cases with malignant and 2 with benign tumors (p >0.05).
  • Detection and analysis of multiple tumor-specific markers in serum and tissue can give useful clinical information for the management of ovarian carcinoma and can also improve the sensitivity and specificity of these markers.
  • [MeSH-major] Biomarkers, Tumor. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms
  • [MeSH-minor] CA-125 Antigen / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Mucin-1 / blood. NM23 Nucleoside Diphosphate Kinases. Nucleoside-Diphosphate Kinase / analysis. Prognosis. Prospective Studies. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Protein p53 / blood. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436409.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Mucin-1; 0 / NM23 Nucleoside Diphosphate Kinases; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.4.6 / NME1 protein, human; EC 2.7.4.6 / Nucleoside-Diphosphate Kinase
  •  go-up   go-down


80. Hascalik S, Celik O, Sarac K, Meydanli MM, Alkan A, Mizrak B: Metabolic changes in pelvic lesions: findings at proton MR spectroscopic imaging. Gynecol Obstet Invest; 2005;60(3):121-7
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Spectroscopy analysis of serous, mucinous and undifferentiated carcinoma of the ovary revealed Cho, lactate and lipid signals, but granulosa-theca cell tumor showed only a lipid signal.
  • The Cho signal was obtained from only 3 patients with mature cystic teratoma but none of the other benign ovarian tumors and pelvic abscesses.
  • A lipid signal was detected in 3 patients diagnosed with pelvic abscess and all benign ovarian tumors.
  • CONCLUSION: MRS demonstrates significant differences in metabolite concentration between benign and malignant ovarian tumors and pelvic abscesses.
  • MRS may therefore be helpful in the differential diagnosis of adnexal lesions.
  • [MeSH-major] Magnetic Resonance Spectroscopy. Pelvic Neoplasms / metabolism. Pelvic Neoplasms / pathology
  • [MeSH-minor] Abdominal Abscess / metabolism. Abdominal Abscess / pathology. Adult. Aged. Choline / metabolism. Creatine / metabolism. Dermoid Cyst / metabolism. Dermoid Cyst / pathology. Diagnosis, Differential. Endometriosis / metabolism. Endometriosis / pathology. Female. Granular Cell Tumor / metabolism. Granular Cell Tumor / pathology. Humans. Lipid Metabolism. Middle Aged. Neoplasms, Cystic, Mucinous, and Serous / metabolism. Neoplasms, Cystic, Mucinous, and Serous / pathology. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Protons. Teratoma / metabolism. Teratoma / pathology

  • Hazardous Substances Data Bank. CREATINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15920339.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Protons; MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


81. Liu HD, Yan Y, Cao XF, Tan PZ, Wen HX, Lv CM, Li XM, Liu GY: [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9]. Sheng Li Xue Bao; 2010 Dec 25;62(6):524-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9].
  • The aim of the present study is to investigate the expression of a novel estrogen receptor, G protein-coupled receptor 30 (GPR30) and its correlation with matrix metalloproteinases-9 (MMP-9) in epithelial ovarian cancer (EOC).
  • Ovary tissues were obtained from 39 female patients, including 30 cases of EOC and 9 cases of benign ovarian tumor.
  • Four normal ovary tissues were used as control.
  • The results showed that GPR30 overexpression rate in EOC cases was significantly higher than those in benign ovarian tumor and normal ovary cases.
  • Whereas MMP-9 overexpression rate in EOC cases was significantly higher than that in normal ovary cases, without any difference to that in benign ovarian tumor cases.
  • These results suggest that GPR30 may be involved in the invasion and metastasis of EOC, being a potential index of EOC early diagnosis and malignancy grade prediction.
  • [MeSH-major] Biomarkers / metabolism. Matrix Metalloproteinase 9 / metabolism. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Receptors, Estrogen / metabolism. Receptors, G-Protein-Coupled / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21170498.001).
  • [ISSN] 0371-0874
  • [Journal-full-title] Sheng li xue bao : [Acta physiologica Sinica]
  • [ISO-abbreviation] Sheng Li Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers; 0 / GPER protein, human; 0 / Receptors, Estrogen; 0 / Receptors, G-Protein-Coupled; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


82. Li Q, Liu S, Lin B, Yan L, Wang Y, Wang C, Zhang S: Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma. Int J Gynecol Cancer; 2010 Dec;20(9):1482-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and correlation of Lewis y antigen and integrins α5 and β1 in ovarian serous and mucinous carcinoma.
  • INTRODUCTION: This study investigates the expression and the clinical significance of Lewis y and integrins α5 and β1 in serous and mucinous ovarian tumors and then evaluates the association between them.
  • METHODS: Lewis y and integrin α5 and β1 expression are detected on tissues from malignant, borderline, and benign ovarian serous and mucinous tumors and normal tissues.
  • RESULTS: Lewis y was mainly expressed in ovarian serous and mucinous cancers (88.33%); its positive rate was obviously higher than rates in the borderline (60.00%, P < 0.05) and benign ovarian tumors (35.00%, P < 0.01) and normal ovarian tissues (0, P < 0.01) and was not associated with clinicopathological characteristics.
  • Integrins α5 (85.00%) and β1 (81.67%) were also mainly expressed in ovarian serous and mucinous cancers; their positive rates were all obviously higher than those in benign ovarian tumors (60.00% and 55.00%, respectively; all P < 0.05) and normal tissues (40.00% and 30.00%, respectively; all P < 0.01).
  • The expression intensity of Lewis y and integrins α5 and β1 was significant with clinical stage and differentiation degree (all P < 0.05) in ovarian cancer; positive significant correlation between Lewis y antigen and integrins α5 and β1 was observed in serous and mucinous ovarian cancer tissues.
  • CONCLUSIONS: A close correlation between Lewis y, integrins α5 and β1, and ovarian cancer was observed.
  • Lewis y can influence the biological behavior of a tumor cell as an important composition of integrins α5 and β1 by some signal pathway, such as promoting cell adhesion and migration, and this study provides theoretical evidence of ovarian cancer biological treatment.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Antigens, CD29 / metabolism. Cystadenocarcinoma, Serous / metabolism. Integrin alpha5 / metabolism. Lewis Blood-Group System / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Case-Control Studies. Female. Humans. Integrin alpha5beta1 / metabolism. Middle Aged. Neoplasm Staging / methods. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119363.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD29; 0 / Biomarkers, Tumor; 0 / Integrin alpha5; 0 / Integrin alpha5beta1; 0 / Lewis Blood-Group System; 0 / Lewis Y antigen
  •  go-up   go-down


83. Jiang GH, Zeng SQ, Tian JZ, Lin CL, Zhang LY, Zhong BL, Liang LB: [Correlation analysis between multi-slice CT perfusion imaging and microvessel density in ovarian tumors]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov;29(11):2197-200
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation analysis between multi-slice CT perfusion imaging and microvessel density in ovarian tumors].
  • OBJECTIVE: To analyze the correlation between the perfusion data and microvessel density (MVD) in ovarian tumors, and investigate the hemodynamic features of the tumors in terms of anatomy and functional CT imaging.
  • METHODS: Six patients with surgically confirmed benign ovarian tumors and 6 with malignant ovarian tumors underwent multi-slice CT perfusion imaging to acquire the perfusion parameters including perfusion, PEI, TTP, BV peak enhancement image(PEI), time to peak(TTP) and blood volume(BV).
  • The tumors were stained and counted by Immunohistochemical staining of the microvessels in the tumor was performed to detect the MVD.
  • RESULTS: s The time-density curves of the benign ovarian tumors increased slowly, reaching the peak at 40 s; the curves of the malignant tumors rose rapidly and continuously and reached the peak at 25 s.
  • The differences in the perfusion data (PEI, TTP, BV) were statistically significant between the benign and malignant tumors (P<0.05).
  • The MVD of the malignant tumors was significantly greater than that of the benign tumors (P<0.05).
  • The mean BV of the malignant ovarian tumor was positively correlated to MVD (r=0.786, P<0.05).
  • CONCLUSION: Multi-slice spiral CT perfusion imaging can provide accurate enhancement data of the ovarian tumors and helps in the diagnosis and differential diagnosis of the ovarian tumors by presenting the changes of the hemodynamic features in the tumors.
  • [MeSH-major] Ovarian Neoplasms / blood supply. Ovarian Neoplasms / radiography. Tomography, Spiral Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19923065.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


84. Liao X, Siu MK, Au CW, Wong ES, Chan HY, Ip PP, Ngan HY, Cheung AN: Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis; 2009 Jan;30(1):131-40
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation.
  • This study aimed at investigating the role of HH molecules in human ovarian carcinogenesis.
  • The expression profiles of HH molecules were examined in ovarian tumor samples and ovarian cancer cell lines and the in vitro effects of HH molecules on cell proliferation, apoptosis, migration, invasion and cell differentiation as well as related downstream target genes were assessed.
  • Overexpression of Patched and Gli1 protein in ovarian cancers correlated with poor survival of the patients (P = 0.008; P = 0.004).
  • Significantly elevated expression of Sonic hedgehog messenger RNA was observed in ovarian cancers compared with normal tissues and benign ovarian tumors and such differential expression was specific to histological types (P < 0.05).
  • Ectopic Gli1 overexpression in ovarian cancer cells conferred increased cell proliferation, cell mobility, invasiveness and change in differentiation in association with increased expression of E-cadherin, vimentin, Bcl-2, caspases as well as beta1 integrin, membrane type 1 matrix metalloproteinase (MT1-MMP) and vascular endothelial growth factor (VEGF).
  • Our data suggested that abnormal HH signaling activation plays important roles in the development and progression of ovarian cancers.
  • Inhibition of the HH pathway molecules might be a valid therapeutic strategy for ovarian cancers.
  • [MeSH-major] Cell Differentiation. Hedgehog Proteins / metabolism. Neoplasm Invasiveness. Ovarian Neoplasms / pathology. Signal Transduction
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunohistochemistry. Prognosis. Receptors, Cell Surface / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19028702.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


85. Obayashi Y, Yabushita H, Kanyama K, Noguchi M, Zhuo L, Kimata K, Wakatsuki A: Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer. Oncol Rep; 2008 May;19(5):1245-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer.
  • The objective of this study was to determine if the level of serum hyaluronan (HA), serum-derived HA-associated protein (SHAP)-HA complex, and urinary trypsin inhibitor (UTI) correlate with the clinical outcome of ovarian cancer patients.
  • Serum and urine samples were obtained from 45 patients with ovarian cancer, 22 patients with benign ovarian tumors and 50 healthy women.
  • The levels of HA, SHAP-HA complex, MMP-9 and TIMP-1 were higher in the ovarian cancer group than in the benign ovarian tumor group.
  • In ovarian cancer patients, the levels of HA, SHAP-HA complex and MMP-9 were higher in the stage III/IV group than in the stage I/II group, and the levels of SHAP-HA complex, MMP-9 and TIMP-1 were higher in the non-responder group than in the responder group.
  • The serum concentration of SHAP-HA complex had a significant correlation with HA, MMP-9 and TIMP-1 in ovarian cancer patients.
  • The elevated level of SHAP-HA complex may indicate the prognosis of recurrence and reflect the tumor metastasis associated with MMP-9 in ovarian cancer patients.
  • [MeSH-major] Alpha-Globulins / biosynthesis. Alpha-Globulins / physiology. Gene Expression Regulation, Neoplastic. Hyaluronic Acid / chemistry. Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Disease-Free Survival. Female. Glycoproteins / chemistry. Humans. Matrix Metalloproteinase 9 / biosynthesis. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425383.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Alpha-Globulins; 0 / Glycoproteins; 39346-44-6 / inter-alpha-inhibitor; 80449-32-7 / urinastatin; 9004-61-9 / Hyaluronic Acid; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


86. Badiglian Filho L, Oshima CT, De Oliveira Lima F, De Oliveira Costa H, De Sousa Damião R, Gomes TS, Gonçalves WJ: Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol Rep; 2009 Feb;21(2):313-20
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.
  • In ovarian cancer, the role played by Wnts and its pathways is not clearly defined.
  • In order to analyze the canonical and noncanonical Wnt pathway in normal ovary, benign ovarian tumor and ovarian cancer, we evaluated the immunohistochemical expression of Wnt1, Frizzled-1 (FZD1), Wnt5a, Frizzled-5 (FZD5) and beta-catenin.
  • Ovarian specimens were obtained from surgeries performed between 1993 and 2004.
  • The patients were divided in three groups: group A, epithelial ovarian cancer (n=38); group B, benign epithelial neoplasia (n=28); and group C, normal ovaries (n=26).
  • Our findings suggest that the pathways related to Wnt5a have an important role in ovarian malignant neoplasia.
  • Furthermore, Wnt5a was found to be a predictor of poor prognosis for ovarian cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Frizzled Receptors / biosynthesis. Neoplasms, Glandular and Epithelial / metabolism. Ovarian Neoplasms / metabolism. Wnt Proteins / biosynthesis. beta Catenin / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Neoplasm Staging. Ovary. Prognosis. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19148501.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Frizzled Receptors; 0 / Wnt Proteins; 0 / beta Catenin
  •  go-up   go-down


87. Youm HS, Cha DS, Han KH, Park EY, Hyon NN, Chong Y: A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman. J Gynecol Oncol; 2008 Dec;19(4):270-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman.
  • Sclerosing stromal tumor (SST) is a rare benign neoplasm of ovarian stromal origin and predominantly affects young women in the second and third decades.
  • This tumor characteristically differentiates itself histologically and clinically from both thecomas and fibromas.
  • We present a case of huge SST of the ovary weighing 10 kg in a 71-year-old postmenopausal woman with a brief review of the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Oct;443(4):549-60 [12910419.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):318-9 [11330969.001]
  • [Cites] Obstet Gynecol. 1975 Jun;45(6):675-9 [1143729.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):305-19 [17717430.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):207-15 [15972425.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Nov;22(5):531-4 [14618669.001]
  • [Cites] Gynecol Oncol. 1976 Sep;4(3):335-9 [964703.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):899-911 [11124069.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Dec;83(3):319-21 [14643050.001]
  • [Cites] Histopathology. 1979 Sep;3(5):367-76 [488921.001]
  • (PMID = 19471655.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676485
  • [Keywords] NOTNLM ; Ovary / Sclerosing stromal tumor
  •  go-up   go-down


88. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, Sanioglu C, Arvas M: Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol; 2010 Dec 30;21(4):248-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
  • OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.
  • METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.
  • Twenty-nine of 87 epithelial ovarian cancer patients were followed up for 6 cycles of paclitaxel-carboplatin chemotherapy.
  • RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.
  • CONCLUSION: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • (PMID = 21278887.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026304
  • [Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker
  •  go-up   go-down


89. Li M, Qi SY, Wang Y, Feng SX, Zhang BZ, Wang R: Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors. Arch Gynecol Obstet; 2005 Jun;272(1):48-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
  • OBJECTIVE: The objectives were to study the expression of vascular endothelial growth factor (VEGF), cyclooxygenase-2 (Cox-2), and Bcl-2 in borderline ovarian tumors (BOTs) and the relationship within them, and to investigate the correlation between expression of VEGF, Cox-2, and Bcl-2, and the clinicopathologic features of BOTs.
  • METHODS: An immunohistochemical technique was used to investigate the expression of VEGF ,Cox-2, and Bcl-2 in 69 borderline, 18 benign, and 27 malignant human ovarian tumor tissues.
  • RESULTS: Expression rate of VEGF protein (59.4%) in BOTs was higher than in benign tumors (27.8%) and was lower than in ovarian carcinomas (92.6%), and there was a significant difference between BOTs and benign ovarian tumors (p < 0.05), and carcinoma (p < 0.01).
  • The expression rate of Cox-2 was significantly higher in ovarian carcinomas (81.5%) than in BOTs (57.9%) and in benign ovarian tumors (38.9%) (p < 0.05).
  • There was a significant difference between the expression of Bcl-2 in ovarian carcinomas and BOTs than that in benign ovarian tumors (p < 0.05).
  • It is feasible to detect VEGF, Cox-2, and Bcl-2 in the diagnosis and to predict the prognosis of BOTs.
  • [MeSH-major] Cyclooxygenase 2 / biosynthesis. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Vascular Endothelial Growth Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682318.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Vascular Endothelial Growth Factors; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


90. Amon LM, Law W, Fitzgibbon MP, Gross JA, O'Briant K, Peterson A, Drescher C, Martin DB, McIntosh M: Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer. PLoS One; 2010 Jun 15;5(6):e11137
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer.
  • BACKGROUND: We used intensive modern proteomics approaches to identify predictive proteins in ovary cancer.
  • METHODOLOGY: Mass spectrometry based quantitative proteomics following extensive protein fractionation was used to compare serum of women with serous ovarian cancer to healthy women and women with benign ovarian tumors.
  • Label-free mass spectrometry was used to compare peritoneal fluid taken from women with serous ovarian cancer and those with benign tumors.
  • CONCLUSION: Proteome profiling applied to symptomatic ovarian cancer cases identifies a large number of up-regulated serum proteins, many of which are or have been confirmed by immunoassays.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):159-66 [11867503.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1481-9 [18311905.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3193-7 [12374688.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):243-52 [12671663.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2223-7 [12727843.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1796-806 [15014034.001]
  • [Cites] Urol Oncol. 2004 Jul-Aug;22(4):337-43 [15283893.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Control Clin Trials. 1997 Jun;18(3):251-70 [9204225.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):583-4; author reply 585-7 [15613439.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):516-9 [15661245.001]
  • [Cites] Brief Funct Genomic Proteomic. 2005 Feb;3(4):322-31 [15814023.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] J Exp Ther Oncol. 2005;5(1):31-8 [16416599.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1570-5 [16452214.001]
  • [Cites] J Proteome Res. 2006 Aug;5(8):2009-18 [16889424.001]
  • [Cites] PLoS Med. 2008 Jun 10;5(6):e123 [18547137.001]
  • [Cites] PLoS One. 2008;3(7):e2633 [18612378.001]
  • [Cites] Clin Cancer Res. 2008 Nov 15;14(22):7574; author reply 7577-9 [18948385.001]
  • [Cites] Methods Mol Biol. 2009;492:309-20 [19241042.001]
  • [Cites] Mol Cell Proteomics. 2009 Mar;8(3):451-66 [18984577.001]
  • [Cites] Mol Cell Proteomics. 2009 Apr;8(4):661-9 [19047685.001]
  • [Cites] PLoS Med. 2009 Jul;6(7):e1000114 [19636370.001]
  • [Cites] Mol Cell Proteomics. 2009 Nov;8(11):2405-17 [19608599.001]
  • [Cites] Nat Rev Cancer. 2010 Jan;10(1):2-3 [20050335.001]
  • [Cites] J Natl Cancer Inst. 2010 Jan 6;102(1):26-38 [20042715.001]
  • [Cites] Clin Chem. 2008 Jan;54(1):44-52 [17981926.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Mar;36(3):259-62 [17113753.001]
  • [Cites] Am J Obstet Gynecol. 2007 Apr;196(4):348.e1-5 [17403417.001]
  • [Cites] Gynecol Oncol. 2007 Jul;106(1):112-8 [17490732.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8 [17671125.001]
  • [Cites] J Proteome Res. 2007 Sep;6(9):3558-65 [17696519.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Chem. 2008 Jan;54(1):53-60 [18024530.001]
  • [Cites] Pancreas. 2008 Jan;36(1):61-9 [18192883.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • (PMID = 20559444.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83636; United States / NCI NIH HHS / CA / P50 CA083636; United States / NCI NIH HHS / CA / U01CA111273; United States / CCR NIH HHS / RC / HHSN261200800001C; United States / NCI NIH HHS / CA / U01 CA111273; United States / NCI NIH HHS / CA / HHSN261200800001E
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; 0 / Insulin-Like Growth Factor Binding Protein 1
  • [Other-IDs] NLM/ PMC2886122
  •  go-up   go-down


91. Nam EJ, Yun MJ, Oh YT, Kim JW, Kim JH, Kim S, Jung YW, Kim SW, Kim YT: Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol; 2010 Mar;116(3):389-94
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
  • PURPOSE: To compare the diagnostic accuracy of positron emission tomography/computed tomography (PET/CT), pelvic Doppler ultrasonography (US), abdomino-pelvic computed tomography (CT), and pelvic magnetic resonance imaging (MRI) for detection of ovarian cancer and to assess the role of PET/CT in evaluating the dissemination of ovarian cancer.
  • PATIENTS AND METHODS: One hundred thirty-three women suspected to have ovarian cancer were enrolled in a prospective study before surgery between March 2005 and August 2007.
  • RESULTS: Histopathology showed benign tumors in 25 patients, borderline tumors in 13 patients, and malignant tumors in 95 patients.
  • In distinguishing malignant/borderline from benign ovarian tumors, the accuracy of PET/CT (0.921) was higher than that of pelvis US (0.830) and abdomino-pelvic CT or pelvis MRI (0.749; P=0.013).
  • Radiologic staging by PET/CT was concordant with surgical staging in 78% of patient and PET/CT revealed 15 (15.8%) unpredicted extra-abdominal lymph node metastasis in 95 patients with ovarian cancer.
  • In addition, PET/CT detected new, unexpected co-existing malignant tumors in five (3.8%) cases including two thyroid tumors, two breast tumors, and one pancreatic neuroendocrine cancer.
  • CONCLUSION: PET/CT is superior to pelvis US, abdomino-pelvic CT, and pelvic MRI for diagnosis of malignant ovarian tumors and is useful in revealing metastatic ovarian cancer and co-existing malignant tumors.
  • Therefore, we suggest that PET/CT could be used during pre-operative evaluation of patients suspected to have ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Staging. Positron-Emission Tomography. ROC Curve. Radiopharmaceuticals. Tomography, X-Ray Computed. Ultrasonography, Doppler. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926121.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


92. Kolwijck E, Zusterzeel PL, Roelofs HM, Hendriks JC, Peters WH, Massuger LF: GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2009 Aug;18(8):2176-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GSTP1-1 in ovarian cyst fluid and disease outcome of patients with ovarian cancer.
  • We studied GSTP1-1 levels in ovarian cyst fluid (oCF), obtained during surgery before chemotherapy, of patients with epithelial ovarian cancer and clinical outcomes were correlated.
  • GSTP1-1 was determined by ELISA in oCF of 56 patients with epithelial ovarian cancer and 109 noncancer controls (21 borderline and 88 benign ovarian tumors).
  • Significantly higher levels of GSTP1-1 were found in the oCF of malignant (median, 383; range, 10-32,695 ng/mL) compared with benign (median, 20; range, 0-1,128 ng/mL) ovarian tumors (P < 0.01).
  • Significantly higher GSTP1-1 levels were found in patients with advanced International Federation of Gynaecologists and Obstetricians stage (P = 0.01), high-grade tumors (P = 0.44), and/or high levels of preoperative CA 125 (P = 0.01).
  • [MeSH-major] Biomarkers, Tumor / analysis. Glutathione S-Transferase pi / metabolism. Neoplasms, Glandular and Epithelial / enzymology. Ovarian Cysts / enzymology. Ovarian Neoplasms / enzymology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Cyst Fluid / chemistry. Cyst Fluid / enzymology. Disease-Free Survival. Enzyme-Linked Immunosorbent Assay. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cysts.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661073.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


93. Chechlinska M, Kaminska J, Markowska J, Kramar A, Steffen J: Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Int J Biol Markers; 2007 Jul-Sep;22(3):172-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.
  • This study aimed to assess the potential value of peritoneal fluid cytokine examination for the differential diagnosis of ovarian tumors and for evaluating residual or recurrent disease after treatment.
  • The cytokines that are commonly elevated in ovarian cancer, VEGF, IL-6, bFGF, IL-8 and M-CSF, and a reference ovarian tumor marker, CA 125, were measured in peritoneal fluids of 53 previously untreated patients with epithelial ovarian cancer, 18 ovarian cancer patients after surgical treatment and chemotherapy, and 17 patients with benign epithelial ovarian tumors.
  • Ovarian cancer peritoneal fluids, as compared to peritoneal fluids of patients with benign ovarian tumors, contained significantly higher concentrations of IL-6, VEGF and CA 125, and significantly lower concentrations of bFGF and M-CSF, but only the levels of IL-6 and VEGF were significantly higher in peritoneal fluids of stage I and II ovarian cancer patients than of patients with benign ovarian conditions.
  • IL-6 at the cutoff level of 400 pg/mL discriminated benign and malignant ovarian tumors with 92% sensitivity and 60% specificity, while VEGF at the cutoff of 400 pg/mL had 90% sensitivity and 80% specificity.
  • IL-6 and VEGF measurements in peritoneal fluids might be useful for the differential diagnosis of malignant and benign ovarian conditions, but not for residual or recurrent disease examination.
  • [MeSH-major] Ascitic Fluid / immunology. Cytokines / analysis. Neoplasm Recurrence, Local / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / blood. CA-125 Antigen / analysis. CA-125 Antigen / biosynthesis. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Interleukin-6 / immunology. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Vascular Endothelial Growth Factors / analysis. Vascular Endothelial Growth Factors / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922459.001).
  • [ISSN] 0393-6155
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Cytokines; 0 / Interleukin-6; 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


94. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC: Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol; 2007 Aug;106(2):311-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma.
  • OBJECTIVE: Unlike other histological types of epithelial ovarian carcinoma, ovarian clear cell carcinoma is known to have very poor response to therapy even when discovered in its early stages.
  • Since tumor hypoxia has been shown to be strongly associated with poor prognosis, deregulation of the representative factor of tissue hypoxia; hypoxia-inducible factor 1 alpha (HIF-1alpha) and related protein; Von Hippel-Lindau (VHL) may be associated with poor prognosis of ovarian clear cell carcinoma.
  • METHODS: Immunolocalization of both HIF-1alpha and VHL was performed on 56 cases of paraffin-embedded tissue sections of four different histological types of epithelial ovarian carcinoma and 5 cases of benign ovarian tumors as a control.
  • Quantitative RT-PCR analysis of both HIF1A and VHL was performed on RNA isolated from 61 microdissected frozen tissues of four different histological types of epithelial ovarian carcinoma and 6 cases of normal ovarian epithelial cells.
  • RESULTS: HIF-1alpha expression levels were significantly higher in ovarian clear cell carcinoma than in other histological types (P=0.001).
  • There was a negative correlation between HIF-1alpha and VHL in serous (r=-0.661, P=0.027) and in endometrioid carcinoma (r=-0.657 P=0.039), but no correlation was found between HIF-1alpha and VHL expression levels in ovarian clear cell carcinoma (P=0.60).
  • CONCLUSIONS: The results suggest that the role of hypoxia may change according to the histological type of ovarian carcinoma.
  • High expression of HIF-1alpha and its independence from VHL in ovarian clear cell carcinoma may confer chemoresistance in this histological type.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Nov 15;59(22):5830-5 [10582706.001]
  • [Cites] Med Hypotheses. 2006;66(2):380-3 [16229963.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):411-21 [10934146.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1830-2 [11280732.001]
  • [Cites] Science. 2001 Apr 20;292(5516):468-72 [11292861.001]
  • [Cites] Biochem J. 2002 Feb 15;362(Pt 1):71-9 [11829741.001]
  • [Cites] Cancer. 2003 Mar 15;97(6):1573-81 [12627523.001]
  • [Cites] Int J Cancer. 2003 Jun 10;105(2):176-81 [12673675.001]
  • [Cites] Cancer Treat Rev. 2003 Aug;29(4):297-307 [12927570.001]
  • [Cites] Cancer. 1977 Dec;40(6):3019-29 [589565.001]
  • [Cites] CA Cancer J Clin. 1980 Jan-Feb;30(1):2-15 [6766347.001]
  • [Cites] Gynecol Oncol. 1989 Nov;35(2):199-203 [2807010.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):141-9 [8276286.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] Hum Mol Genet. 1994 Dec;3(12):2169-73 [7881415.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4 [7539918.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):412-7 [8774649.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2157-63 [8918409.001]
  • [Cites] Kidney Int. 1997 Feb;51(2):560-3 [9027739.001]
  • [Cites] Nature. 1998 Jul 30;394(6692):485-90 [9697772.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):255-8 [9740700.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6573-86 [9822602.001]
  • [Cites] Nature. 1999 May 20;399(6733):271-5 [10353251.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1973-81 [16123149.001]
  • [Cites] Sci STKE. 2005 Oct 18;2005(306):re12 [16234508.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):343-7 [16051334.001]
  • [Cites] Cancer. 2000 Jun 1;88(11):2606-18 [10861440.001]
  • (PMID = 17532031.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA103595; United States / NCI NIH HHS / CA / R33 CA103595-04; United States / NCI NIH HHS / CA / CA103595-04; United States / NCI NIH HHS / CA / CA105009-030002; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA105009-030002; United States / PHS HHS / / P50105009; United States / NCI NIH HHS / CA / R01 CA133057; United States / NCI NIH HHS / CA / R33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / RNA, Messenger; EC 6.3.2.19 / VHL protein, human; EC 6.3.2.19 / Von Hippel-Lindau Tumor Suppressor Protein
  • [Other-IDs] NLM/ NIHMS28316; NLM/ PMC1995602
  •  go-up   go-down


95. Choudhrie L, Mahajan NN, Solomon MV, Thomas A, Kale AJ, Mahajan K: Ovarian ligament adenomyoma: a case report. Acta Chir Belg; 2007 Jan-Feb;107(1):84-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian ligament adenomyoma: a case report.
  • BACKGROUND: Adenomyoma is a benign tumour composed of smooth muscle and benign endometrium.
  • CASE: We report a case of extra-uterine adenomyoma of the ovarian ligament, which was an incidental finding during a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a benign ovarian tumour in a postmenopausal woman.
  • There have been no cases of adenomyoma in the ovarian ligament reported until now.
  • [MeSH-major] Adenomyoma / pathology. Ligaments / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17405609.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


96. Wang P, Wu X, Chen W, Liu J, Wang X: The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Gynecol Oncol; 2007 Mar;104(3):714-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
  • OBJECTIVE: To investigate the lysophosphatidic acid (LPA) receptors expression situation and their biological significance in human ovarian cancer cell lines and in human epithelial ovarian neoplasms.
  • METHODS: The reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting were employed to measure the expression levels of LPA(1), LPA(2) and LPA(3) mRNA, LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines (3AO, SKOV3 and OVCAR3) and in human epithelial ovarian neoplasms.
  • The immunocytochemical method was used to detect LPA(2) and LPA(3) protein expression in cultured human ovarian cancer cell lines.
  • RESULTS: RT-PCR revealed that all ovarian cancer cell lines expressed LPA(1), LPA(2) and LPA(3) mRNA.
  • The positive rates (100%; 86.4%; 88.2%) of LPA(1) mRNA in normal ovarian tissue, benign tumor and ovarian cancer were no significant difference (p>0.05).
  • The expression level of LPA(1) mRNA was significantly higher in normal ovarian tissue compared with that in benign tumor and in ovarian cancer tissue (p<0.01).
  • LPA(1) expression level was no significant difference in both benign tumor and ovarian cancer tissue (p>0.05).
  • LPA(2) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01); LPA(2) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(3) mRNA-positive rates (92.6%) and expression level were significantly higher in ovarian cancer compared with that in benign tumor (31.8%) and in normal ovarian tissue (31.3%) (p<0.01), LPA(3) mRNA-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • LPA(1) mRNA expression level was significantly decreased compared with that of LPA(2) and LPA(3) in ovarian cancer (p<0.01); Western blotting clearly revealed that all ovarian cancer cell lines showed LPA(2) and LPA(3) protein.
  • The positive rates and expression level of LPA(2) and LPA(3) protein were significantly increased in ovarian cancer (92.6%; 92.6%) compared with that in benign tumor (45.5%; 45.5%) and that in normal ovarian tissue (43.8%; 43.8%) (p<0.01); LPA(2) and LPA(3) protein-positive rates and expression level were no significant difference in both benign tumor and normal ovarian tissue (p>0.05).
  • The mRNA and protein expression of LPA(2) and LPA(3) in stages III and IV was significantly higher than that in stages I and II epithelial ovarian cancer (p<0.05).
  • CONCLUSION: LPA(1), LPA(2) and LPA(3) mRNA and protein expressed widely in human epithelial ovarian neoplasms.
  • LPA(2) and LPA(3) may be involved in the development and progression of human ovarian cancer.
  • There was a significant correlation between LPA(2), LPA(3) and invasion and metastasis of epithelial ovarian cancer.
  • LPA(2) and LPA(3) may be a prognostic indicator in patients with epithelial ovarian cancer.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Receptors, Lysophosphatidic Acid / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204312.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Lysophosphatidic Acid
  •  go-up   go-down


97. Zhang B, Pan JS, Liu JY, Han SP, Hu G, Wang B: Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer. Methods Find Exp Clin Pharmacol; 2006 Nov;28(9):619-25
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of chemotherapy and/or radiotherapy on survivin expression in ovarian cancer.
  • In this study, the correlation between the level of survivin expression and degree of apoptosis was investigated in three ovarian cancer lines (two chemoresistant cell lines SKOV-3 and OVCAR-3, as well as one chemosensitive cell line OV2008) treated with 5 microg/ml of cisdiamminedichloroplatinum (cisplatin, CDDP) for 24 h, 2 Gy of (60)Co irradiation, or 5 microg/ml CDDP for 3 h plus 2 Gy of (60)Co, respectively.
  • We also evaluated the survivin mRNA abundance in patients with advanced ovarian cancers during CDDP treatment.
  • In the ovarian cancer cell lines, survivin mRNA abundance and protein contents were significantly increased after the treatments while the apoptotic rates did not change in SKOV-3 and OVCAR-3.
  • Survivin mRNA was not detectable in normal ovarian tissues and benign ovarian tumors.
  • However, it was observed in the resected tumor specimens from 20 patients with advanced ovarian cancer.
  • These results suggested that survivin may play an important role in the resistance to chemotherapy and radiotherapy in ovarian cancer cell lines and in the progression of ovarian tumors.
  • Survivin may also provide a pivotal prognostic implication for epithelial ovarian carcinomas.
  • [MeSH-major] Microtubule-Associated Proteins / genetics. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200728.001).
  • [ISSN] 0379-0355
  • [Journal-full-title] Methods and findings in experimental and clinical pharmacology
  • [ISO-abbreviation] Methods Find Exp Clin Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


98. Ma L, Liu FR, Zhang SL: [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients]. Zhonghua Bing Li Xue Za Zhi; 2005 Dec;34(12):785-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of circulating hypermethylated tumor-specific RASSF1A DNA in ovarian cancer patients].
  • OBJECTIVE: To detect hypermethylated tumor-specific RASSF1A DNA in the circulation and its significance in ovarian cancers patients.
  • METHODS: Methylation-specific polymerase chain reaction (MSP) was used to study the hypermethylation of RASSF1A in preoperative serum samples from 51 ovarian cancer patients.
  • RESULTS: The RASSF1A gene was not methylated in peripheral blood samples from 51 normal patients and 51 patients with benign ovarian tumors.
  • Hypermethylation of RASSF1A gene was found in circulating tumor-specific DNA in 43.1% of patients (22 out of 51 cases) with ovarian cancers (P < 0.05).
  • There was no difference in hypermethylation of RASSF1A gene amongst various ovarian cancer subtypes (P < 0.05).
  • On the other hand, hypermethylation of RASSF1A gene was more frequently encountered in stage III and IV than stage I and II tumors (P < 0.05).
  • CONCLUSIONS: There is a higher frequency of RASSF1A hypermethylation in circulating tumor-specific DNA of ovarian cancer patients.
  • RASSF1A has been postulated to play an important role as tumor suppressor gene and can be silenced by promoter hypermethylation.
  • Such observation may carry diagnostic and prognostic implications when assessing ovarian tumors.
  • [MeSH-major] DNA Methylation. Ovarian Neoplasms / blood. Tumor Suppressor Proteins / blood
  • [MeSH-minor] Carcinoma, Endometrioid / blood. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Mucinous / blood. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / pathology. Female. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16545186.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


99. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, Tamura R, Timor-Tritsch I, Schwartz PE: The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer. Am J Obstet Gynecol; 2005 Apr;192(4):1214-21; discussion 1221-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of ultrasound evaluation in the detection of early-stage epithelial ovarian cancer.
  • OBJECTIVE: Epithelial ovarian cancer kills more women than all other gynecologic malignancies combined because of our inability to detect early-stage disease.
  • Ultrasonography has demonstrated usefulness in the detection of ovarian cancer in asymptomatic women, but its value for the detection of early-stage epithelial ovarian cancer in women of increased risk is uncertain.
  • We examined the usefulness of sonography in the detection of early-stage epithelial ovarian cancer in asymptomatic high-risk women who participated in the National Ovarian Cancer Early Detection Program.
  • STUDY DESIGN: Only asymptomatic women of increased risk for the development of ovarian cancer with initial normal gynecologic and ultrasound examinations were eligible to participate in the institutional review board-approved National Ovarian Cancer Early Detection Program.
  • Increased risk includes women with at least 1 affected first-degree relative with ovarian cancer; a personal history of breast, ovarian, or colon cancer; > or =1 affected first- and second-degree relatives with breast and or ovarian cancer; inheritance of a breast cancer mutation from an affected family member, or membership within a recognized cancer syndrome.
  • A total of 98 women with persistent adnexal masses were identified, and 49 invasive surgical procedures were performed that diagnosed 37 benign ovarian tumors and 12 gynecologic malignancies.
  • All cancers were detected in asymptomatic women who had normal ultrasound and physical examinations 12 and 6 months before the cancer diagnosis.
  • The detected malignancies were fallopian tube carcinoma (stage IIIC; n = 4 women), primary peritoneal carcinoma (n = 4 women; stage IIIA, 1 woman; stage IIIB, 2 women; stage IIIC, 1 woman), epithelial ovarian cancer (stages IIIA and IIIB; n = 2 women), and endometrial adenocarcinoma (stage IA; n = 2 women).
  • CONCLUSION: This study demonstrates the limited value of diagnostic ultrasound examination as an independent modality for the detection of early-stage epithelial ovarian cancer in asymptomatic women who are at increased risk for disease.
  • [MeSH-major] Mass Screening / methods. Neoplasms, Glandular and Epithelial / pathology. Neoplasms, Glandular and Epithelial / ultrasonography. Ovarian Neoplasms / pathology. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Age Distribution. Aged. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Ultrasonography, Doppler, Color

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15846205.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA83639; United States / NCI NIH HHS / CA / R01 CA01015; United States / NCI NIH HHS / CA / R01 CA82562; United States / NCI NIH HHS / CA / R01 CA89503; United States / NCI NIH HHS / CA / UO1CA85133
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


100. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ: Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev; 2005 Feb;14(2):306-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
  • Epithelial ovarian cancer (EOC) is the leading cause of death among all gynecologic cancers in the United States.
  • Serum cancer antigen 125 (CA125) and a soluble isoform of the epidermal growth factor receptor (p110 sEGFR) have been studied individually as biomarkers of ovarian cancer.
  • In this study, we compare serum CA125 levels and sEGFR concentrations in women with EOC to women with benign gynecologic conditions of ovarian and non-ovarian origin.
  • We show that serum sEGFR concentrations are lower in patients with EOC than in women with benign gynecologic conditions, whereas serum CA125 levels are higher in patients to EOC compared with women with benign gynecologic conditions.
  • These data also reveal that age and serum sEGFR concentrations modify the association between CA125 levels and EOC versus benign gynecologic disease.
  • Hence, age- and sEGFR-dependent CA125 cutoff thresholds improve the ability of CA125 to discern EOC patients from women with benign ovarian tumors and non-ovarian gynecologic conditions.
  • Our analyses show that parallel testing with fixed sEGFR and CA125 cutoff thresholds optimizes sensitivity to detect EOC, whereas serial testing with age- and sEGFR-dependent CA125 cutoff thresholds optimizes test specificity, and overall accuracy to discern patients with EOC from women with benign ovarian and non-ovarian gynecologic conditions.
  • The combined use of serologic sEGFR and CA125, thus, has improved utility for screening and diagnosing EOC, which may increase the positive predictive value of a multimodal screening program that incorporates these biomarkers to detect and subsequently differentiate benign from malignant ovarian tumors.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / diagnosis. Receptor, Epidermal Growth Factor / blood

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583
  • (PMID = 15734951.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / KO7 CA82520; United States / PHS HHS / / R01 57534; United States / NCI NIH HHS / CA / R03 CA82091; United States / NCI NIH HHS / CA / R21 CA82520; United States / NCI NIH HHS / CA / UO1 CA85133
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Protein Isoforms; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement